Actifed DM
Generic Name: Cough/Cold Combinations
This monograph includes information on the following:
Note: Products containing phenylpropanolamine were removed from the U.S. and Canadian Markets in November 2000.{61}
1) Brompheniramine, Phenylephrine and Codeine
2) Brompheniramine, Phenylephrine, Codeine and Guaifenesin *
3) Brompheniramine, Phenylephrine, Hydrocodone and Guaifenesin *
4) Brompheniramine, Pseudoephedrine, and Dextromethorphan †
5) Carbinoxamine, Pseudoephedrine, and Dextromethorphan †
6) Chlorpheniramine and Codeine *
7) Chlorpheniramine and Dextromethorphan †
8) Chlorpheniramine and Hydrocodone †
9) Chlorpheniramine, Ephedrine, and Guaifenesin †
10) Chlorpheniramine, Ephedrine, Phenylephrine, and Carbetapentane †
11) Chlorpheniramine, Ephedrine, Phenylephrine, Dextromethorphan, Ammonium Chloride, and Ipecac †
12) Chlorpheniramine, Pheniramine, Pyrilamine, Phenylephrine, Hydrocodone, Salicylamide, Caffeine, and Ascorbic Acid †
13) Chlorpheniramine, Phenylephrine, Codeine, and Ammonium Chloride †
14) Chlorpheniramine, Phenylephrine, Codeine, and Potassium Iodide †
15) Chlorpheniramine, Phenylephrine, and Dextromethorphan †
16) Chlorpheniramine, Phenylephrine, Dextromethorphan, and Guaifenesin †
17) Chlorpheniramine, Phenylephrine, Dextromethorphan, Guaifenesin, and Ammonium Chloride †
18) Chlorpheniramine, Phenylephrine, and Hydrocodone †
19) Chlorpheniramine, Phenylephrine, Hydrocodone, Acetaminophen, and Caffeine †
20) Chlorpheniramine, Pseudoephedrine, and Codeine
21) Chlorpheniramine, Pseudoephedrine, Codeine and Acetaminophen *
22) Chlorpheniramine, Pseudoephedrine, and Dextromethorphan
23) Chlorpheniramine, Pseudoephedrine, Dextromethorphan, and Acetaminophen
24) Chlorpheniramine, Pseudoephedrine, Dextromethorphan, and Guaifenesin *
25) Chlorpheniramine, Pseudoephedrine, and Hydrocodone †
26) Chlorpheniramine, Pyrilamine, Phenylephrine, Pseudoephedrine and Hydrocodone †
27) Codeine, Ammonium Chloride, and Guaifenesin *
28) Codeine and Guaifenesin †
29) Dextromethorphan and Acetaminophen
30) Dextromethorphan and Guaifenesin
31) Dextromethorphan and Iodinated Glycerol †
32) Diphenhydramine, Codeine, and Ammonium Chloride *
33) Diphenhydramine, Dextromethorphan, and Ammonium Chloride *
34) Doxylamine, Codeine, and Acetaminophen *
35) Doxylamine, Etafedrine, and Hydrocodone *
36) Doxylamine, Pseudoephedrine, Dextromethorphan, and Acetaminophen
37) Ephedrine and Guaifenesin †
38) Hydrocodone and Guaifenesin †
39) Hydrocodone and Homatropine †
40) Hydrocodone and Potassium Guaiacolsulfonate †
41) Hydrocodone *
42) Pheniramine, Codeine, and Guaifenesin *
43) Pheniramine, Phenylephrine, Codeine, Sodium Citrate, Sodium Salicylate, and Caffeine †
44) Pheniramine, Phenylephrine, and Dextromethorphan *
45) Pheniramine, Pyrilamine, Hydrocodone, Potassium Citrate, and Ascorbic Acid †
46) Pheniramine, Pyrilamine and Phenyltoloxamine †
47) Phenylephrine, Codeine and Guaifenesin †
48) Phenylephrine and Guaifenesin †
49) Phenylephrine and Hydrocodone
50) Phenylephrine, Hydrocodone, and Guaifenesin
51) Phenyltoloxamine and Hydrocodone *
52) Promethazine and Codeine †
53) Promethazine, Codeine, and Potassium Guaiacolsulfonate *
54) Promethazine and Dextromethorphan †
55) Promethazine and Potassium Guaiacolsulfonate *
56) Promethazine and Phenylephrine †
57) Promethazine, Phenylephrine, and Codeine †
58) Promethazine, Phenylephrine, and Potassium Guaiacolsulfonate *
59) Pseudoephedrine, Codeine, and Guaifenesin
60) Pseudoephedrine and Dextromethorphan
61) Pseudoephedrine, Dextromethorphan, and Acetaminophen
62) Pseudoephedrine, Dextromethorphan, and Guaifenesin
63) Pseudoephedrine, Dextromethorphan, Guaifenesin, and Acetaminophen
64) Pseudoephedrine and Guaifenesin
65) Pseudoephedrine, Hydrocodone, and Guaifenesin †
66) Pseudoephedrine, Hydrocodone, and Potassium Guaiacolsulfonate †
67) Pyrilamine and Codeine †
68) Pyrilamine, Phenylephrine, Hydrocodone, and Ammonium Chloride *
69) Pyrilamine, Pseudoephedrine, Dextromethorphan, and Acetaminophen †
70) Triprolidine, Pseudoephedrine, and Codeine
71) Triprolidine, Pseudoephedrine, Codeine, and Guaifenesin *
{62}
VA CLASSIFICATION
Brompheniramine, Phenylephrine and Codeine (Systemic)
Primary: RE502
Brompheniramine, Phenylephrine, Codeine, and Guaifenesin (Systemic)
Primary: RE504
Brompheniramine, Phenylephrine, Hydrocodone and Guaifenesin (Systemic)
Primary: RE504
Brompheniramine, Pseudoephedrine, and Dextromethorphan (Systemic)
Primary: RE502
Carbinoxamine, Pseudoephedrine, and Dextromethorphan (Systemic)
Primary: RE502
Chlorpheniramine and Codeine (Systemic)
Primary: RE507
Chlorpheniramine and Dextromethorphan (Systemic)
Primary: RE507
Chlorpheniramine, Ephedrine, and Guaifenesin (Systemic)
Primary: RE503
Chlorpheniramine, Ephedrine, Phenylephrine, and Carbetapentane (Systemic)
Primary: RE502
Chlorpheniramine, Ephedrine, Phenylephrine, Dextromethorphan, Ammonium Chloride, and Ipecac (Systemic)
Primary: RE504
Chlorpheniramine and Hydrocodone (Systemic)
Primary: RE301
Chlorpheniramine, Pheniramine, Pyrilamine, Phenylephrine, Hydrocodone, Salicylamide, Caffeine, and Ascorbic Acid (Systemic)
Primary: RE301
Chlorpheniramine, Phenylephrine, Codeine, and Ammonium Chloride (Systemic)
Primary: RE301
Chlorpheniramine, Phenylephrine, Codeine, and Potassium Iodide (Systemic)
Primary: RE301
Chlorpheniramine, Phenylephrine, and Dextromethorphan (Systemic)
Primary: RE502
Chlorpheniramine, Phenylephrine, Dextromethorphan, and Guaifenesin (Systemic)
Primary: RE504
Chlorpheniramine, Phenylephrine, Dextromethorphan, Guaifenesin, and Ammonium Chloride (Systemic)
Primary: RE504
Chlorpheniramine, Phenylephrine, and Hydrocodone (Systemic)
Primary: RE301
Chlorpheniramine, Phenylephrine, Hydrocodone, Acetaminophen, and Caffeine (Systemic)
Primary: RE301
Chlorpheniramine, Pseudoephedrine, and Codeine (Systemic)
Primary: RE301
Chlorpheniramine, Pseudoephedrine, Codeine, and Acetaminophen (Systemic)
Primary: RE506
Chlorpheniramine, Pseudoephedrine, Dextromethorphan, and Acetaminophen (Systemic)
Primary: RE506
Chlorpheniramine, Pseudoephedrine, and Dextromethorphan (Systemic)
Primary: RE502
Chlorpheniramine, Pseudoephedrine, Dextromethorphan, and Guaifenesin (Systemic)
Primary: RE504
Chlorpheniramine, Pseudoephedrine, and Hydrocodone (Systemic)
Primary: RE301
Chlorpheniramine, Pyrilamine, Phenylephrine, Pseudoephedrine and Hydrocodone (Systemic)
Primary: RE502
Codeine, Ammonium Chloride, and Guaifenesin (Systemic)
Primary: RE301
Codeine and Guaifenesin (Systemic)
Primary: RE301
Dextromethorphan and Acetaminophen (Systemic)
Primary: RE302
Dextromethorphan and Guaifenesin (Systemic)
Primary: RE302
Dextromethorphan and Iodinated Glycerol (Systemic)
Primary: RE302
Diphenhydramine, Codeine, and Ammonium Chloride (Systemic)
Primary: RE301
Diphenhydramine, Dextromethorphan, and Ammonium Chloride (Systemic)
Primary: RE502
Doxylamine, Codeine, and Acetaminophen (Systemic)
Primary: RE509
Doxylamine, Etafedrine, and Hydrocodone (Systemic)
Primary: RE502
Doxylamine, Pseudoephedrine, Dextromethorphan, and Acetaminophen (Systemic)
Primary: RE506
Ephedrine and Guaifenesin (Systemic)
Primary: RE516
Hydrocodone and Guaifenesin (Systemic)
Primary: RE301
Hydrocodone and Homatropine (Systemic)
Primary: RE301
Hydrocodone and Potassium Guaiacolsulfonate (Systemic)
Primary: RE301
Pheniramine, Codeine, and Guaifenesin (Systemic)
Primary: RE301
Pheniramine, Phenylephrine, Codeine, Sodium Citrate, Sodium Salicylate, and Caffeine (Systemic)
Primary: RE301
Pheniramine, Phenylephrine, and Dextromethorphan (Systemic)
Primary: RE502
Pheniramine, Pyrilamine, Hydrocodone, Potassium Citrate, and Ascorbic Acid (Systemic)
Primary: RE301
Pheniramine, Pyrilamine, and Phenyltoloxamine (Systemic)
Primary: RE501
Phenylephrine, Codeine and Guaifenesin (Systemic)
Primary: RE513
Phenylephrine and Guaifenesin (Systemic)
Primary: RE516
Phenylephrine and Hydrocodone (Systemic)
Primary: RE512
Phenylephrine, Hydrocodone, and Guaifenesin (Systemic)
Primary: RE301
Phenyltoloxamine and Hydrocodone (Systemic)
Primary: RE301
Promethazine and Codeine (Systemic)
Primary: RE301
Promethazine, Codeine, and Potassium Guaiacolsulfonate (Systemic)
Primary: RE301
Promethazine and Dextromethorphan (Systemic)
Primary: RE507
Promethazine and Potassium Guaiacolsulfonate (Systemic)
Primary: RE599
Promethazine and Phenylephrine (Systemic)
Primary: RE501
Promethazine, Phenylephrine, and Codeine (Systemic)
Primary: RE301
Promethazine, Phenylephrine, and Potassium Guaiacolsulfonate (Systemic)
Primary: RE503
Pseudoephedrine, Codeine, and Guaifenesin (Systemic)
Primary: RE301
Pseudoephedrine and Dextromethorphan (Systemic)
Primary: RE512
Pseudoephedrine, Dextromethorphan, and Acetaminophen (Systemic)
Primary: RE515
Pseudoephedrine, Dextromethorphan, and Guaifenesin (Systemic)
Primary: RE513
Pseudoephedrine, Dextromethorphan, Guaifenesin, and Acetaminophen (Systemic)
Primary: RE514
Pseudoephedrine and Guaifenesin (Systemic)
Primary: RE516
Pseudoephedrine, Hydrocodone, and Guaifenesin (Systemic)
Primary: RE301
Pseudoephedrine, Hydrocodone, and Potassium Guaiacolsulfonate
Primary: RE301
Pyrilamine and Codeine (Systemic)
Primary: RE301
Pyrilamine, Phenylephrine, Hydrocodone, and Ammonium Chloride (Systemic)
Primary: RE301
Pyrilamine, Pseudoephedrine, Dextromethorphan, and Acetaminophen (Systemic)
Primary: RE506
Triprolidine, Pseudoephedrine, and Codeine (Systemic)
Primary: RE301
Triprolidine, Pseudoephedrine, Codeine, and Guaifenesin (Systemic)
Primary: RE301
Note: Due to the large number of cough/cold products available and the different ingredients they contain, the listing that normally appears in this section has been omitted to save space. To aid the reader in readily finding the combination(s) and/or product(s) of interest, these have been grouped in the Category section and in the Advice for the Patient monograph according to the following major categories:
• Antihistaminic (H 1-receptor)-decongestant-antitussive
• Antihistaminic (H 1-receptor)-decongestant-expectorant
• Antihistaminic (H 1-receptor)-decongestant-antitussive-expectorant
• Antihistaminic (H 1-receptor)-decongestant-antitussive-expectorant-analgesic
• Antihistaminic (H 1-receptor)-decongestant-antitussive-analgesic
• Antihistaminic (H 1-receptor)-decongestant-expectorant-analgesic
• Antihistaminic (H 1-receptor)-antitussive
• Antihistaminic (H 1-receptor)-antitussive-expectorant
• Antihistaminic (H 1-receptor)-antitussive-analgesic
• Antihistaminic (H 1-receptor)-expectorant
• Antitussive-expectorant
• Antitussive-analgesic
• Antitussive-anticholinergic
• Decongestant-antitussive
• Decongestant-antitussive-expectorant
• Decongestant-antitussive-expectorant-analgesic
• Decongestant-antitussive-analgesic
• Decongestant-expectorant
• Decongestant-expectorant-analgesic
Other combination products that are used in the symptomatic treatment of colds, but which do not contain either an antitussive or an expectorant, can be found in Antihistamines and Decongestants (Systemic) ; Antihistamines, Decongestants, and Analgesics (Systemic) ; Antihistamines, Decongestants, and Anticholinergics (Systemic) ; and Decongestants and Analgesics (Systemic) .
Note: For a listing of dosage forms and brand names by country availability, see Dosage Forms section(s).
*Not commercially available in the U.S.
†Not commercially available in Canada.
Category:
Antihistaminic (H 1-receptor)-decongestant—Pheniramine, Pyrilamine, and Phenyltoloxamine; Promethazine and Phenylephrine;
Antihistaminic (H 1-receptor)-decongestant-antitussive— Brompheniramine, Phenylephrine and Codeine; Brompheniramine, Pseudoephedrine, and Dextromethorphan; Carbinoxamine, Pseudoephedrine, and Dextromethorphan; Chlorpheniramine, Pyrilamine, Phenylephrine, Pseudoephedrine and Hydrocodone; Chlorpheniramine, Ephedrine, Phenylephrine, and Carbetapentane; Chlorpheniramine, Phenylephrine, and Dextromethorphan; Chlorpheniramine, Phenylephrine, and Hydrocodone; Chlorpheniramine, Pseudoephedrine, and Codeine; Chlorpheniramine, Pseudoephedrine, and Dextromethorphan; Chlorpheniramine, Pseudoephedrine, and Hydrocodone; Doxylamine, Etafedrine, and Hydrocodone; Pheniramine, Phenylephrine, and Dextromethorphan; Promethazine, Phenylephrine, and Codeine; Triprolidine, Pseudoephedrine, and Codeine;
Antihistaminic (H 1-receptor)-decongestant-expectorant— Chlorpheniramine, Ephedrine, and Guaifenesin; Promethazine, Phenylephrine, and Potassium Guaiacolsulfonate;
Antihistaminic (H 1-receptor)-decongestant-antitussive-expectorant—Brompheniramine, Phenylephrine, Codeine, and Guaifenesin ; Brompheniramine, Phenylephrine, Hydrocodone, and Guaifenesin; Chlorpheniramine, Ephedrine, Phenylephrine, Dextromethorphan, Ammonium Chloride, and Ipecac; Chlorpheniramine, Phenylephrine, Codeine, and Ammonium Chloride ; Chlorpheniramine, Phenylephrine, Codeine, and Potassium Iodide; Chlorpheniramine, Phenylephrine, Dextromethorphan, and Guaifenesin; Chlorpheniramine, Phenylephrine, Dextromethorphan, Guaifenesin, and Ammonium Chloride; Chlorpheniramine, Pseudoephedrine, Dextromethorphan, and Guaifenesin; Pyrilamine, Phenylephrine, Hydrocodone, and Ammonium Chloride; Triprolidine, Pseudoephedrine, Codeine, and Guaifenesin;
Antihistaminic (H 1-receptor)-decongestant-antitussive-expectorant-analgesic—Pheniramine, Phenylephrine, Codeine, Sodium Citrate, Sodium Salicylate, and Caffeine;
Antihistaminic (H 1-receptor)-decongestant-antitussive-analgesic—Chlorpheniramine, Pheniramine, Pyrilamine, Phenylephrine, Hydrocodone, Salicylamide, Caffeine, and Ascorbic Acid; Chlorpheniramine, Phenylephrine, Hydrocodone, Acetaminophen, and Caffeine; Chlorpheniramine, Pseudoephedrine, Codeine, and Acetaminophen; Chlorpheniramine, Pseudoephedrine, Dextromethorphan, and Acetaminophen; Doxylamine, Pseudoephedrine, Dextromethorphan, and Acetaminophen; Pyrilamine, Pseudoephedrine, Dextromethorphan, and Acetaminophen ;
Antihistaminic (H 1-receptor)-antitussive—Chlorpheniramine and Codeine; Chlorpheniramine and Dextromethorphan ; Chlorpheniramine and Hydrocodone; Phenyltoloxamine and Hydrocodone; Promethazine and Codeine; Promethazine and Dextromethorphan; Pyrilamine and Codeine ;
Antihistaminic (H 1-receptor)-antitussive-expectorant— Diphenhydramine, Codeine, and Ammonium Chloride; Diphenhydramine, Dextromethorphan, and Ammonium Chloride; Pheniramine, Codeine, and Guaifenesin; Pheniramine, Pyrilamine, Hydrocodone, Potassium Citrate, and Ascorbic Acid; Promethazine, Codeine, and Potassium Guaiacolsulfonate;
Antihistaminic (H 1-receptor)-antitussive-analgesic— Doxylamine, Codeine, and Acetaminophen;
Antitussive-expectorant—Codeine, Ammonium Chloride, and Guaifenesin; Codeine and Guaifenesin; Dextromethorphan and Guaifenesin; Dextromethorphan and Iodinated Glycerol; Hydrocodone and Guaifenesin;
Antitussive-analgesic—Dextromethorphan and Acetaminophen;
Antitussive-anticholinergic—Hydrocodone and Homatropine;
Decongestant-antitussive—Phenylephrine and Hydrocodone; Pseudoephedrine and Dextromethorphan;
Decongestant-antitussive-expectorant —Phenylephrine, Codeine and Guaifenesin ; Phenylephrine, Hydrocodone, and Guaifenesin ; Pseudoephedrine, Codeine, and Guaifenesin ; Pseudoephedrine, Dextromethorphan, and Guaifenesin; Pseudoephedrine, Hydrocodone, and Guaifenesin; Pseudoephedrine, Hydrocodone, and Potassium Guaiacolsulfonate;
Decongestant-antitussive-expectorant-analgesic —Pseudoephedrine, Dextromethorphan, Guaifenesin, and Acetaminophen;
Decongestant-antitussive-analgesic —Pseudoephedrine, Dextromethorphan, and Acetaminophen;
Decongestant-expectorant—Ephedrine and Guaifenesin; Phenylephrine and Guaifenesin; Pseudoephedrine and Guaifenesin; {62}
Indications
Accepted
Note: Products containing phenylpropanolamine were removed from the U.S. and Canadian Markets in November 2000.{61}
Cough (treatment)—Combination products containing antitussives and/or expectorants may be indicated for the symptomatic relief of cough due to colds and minor upper respiratory infections. {01}
Cough and nasal congestion (treatment)—Combination products containing antitussives and/or expectorants, and nasal decongestants may be indicated for the symptomatic relief of cough and nasal congestion due to the common cold and other respiratory infections. Also, products containing antihistamines may provide relief of the cough, nasal congestion, rhinorrhea, and sneezing associated with allergy and the common cold. However, controlled clinical studies have not demonstrated that antihistamines are significantly more effective than placebo in relieving cold symptoms. {02}
Cold symptoms (treatment)—Combination products containing antihistamines, antitussives or expectorants, nasal decongestants, and analgesics may be indicated for the temporary relief of coughs, nasal congestion, and associated aches, pains, and general discomfort due to colds, flu, or allergy. The antihistamine in these cold combinations may provide relief of nasal congestion, rhinorrhea, and sneezing. It may also serve as an adjunct because of its anticholinergic drying effects. However, in many cough/cold combinations, the dosage level of the antihistamine is below that required to obtain a significant effect. Also, controlled clinical studies have not demonstrated that antihistamines are significantly more effective than placebo in relieving cold symptoms. {02}
Unaccepted
Cough/cold combination products that contain both an antitussive and an expectorant usually do not offer any advantage over products that contain only one of these agents. In some cases, their combination may be detrimental in the treatment of coughs, since antitussives should be used only in the treatment of dry coughs and not for productive coughs.
Some products containing an anticholinergic have been used to help dry excessive nasal secretions associated with the common cold and allergic rhinitis; however, the efficacy of anticholinergics for this use in these combination products has not been established. In most products, the anticholinergic is included in doses below the therapeutic level in an attempt to prevent abuse by deliberate overdosage (e.g., in combinations containing a narcotic antitussive) {23}.
Combination products that contain an analgesic are generally not recommended for regular use for the treatment of cold symptoms during the common cold or acute allergic rhinitis since they may mask fever, which may indicate a secondary bacterial infection.
Ammonium chloride, calcium iodide, citric acid, guaiacol carbonate, iodinated glycerol, ipecac, potassium citrate, potassium guaiacolsulfonate, potassium iodide, and sodium citrate are included as expectorants in these combinations; however, the Food and Drug Administration (FDA) has not found them to be useful for this indication. Therefore, FDA has requested manufacturers to reformulate their products to replace these ingredients with guaifenesin. {08}
Pharmacology/Pharmacokinetics
Antihistamine-containing—See Antihistamines (Systemic) .
Decongestant-containing—See:
• Ephedrine in Bronchodilators, Adrenergic (Systemic) .
• Pseudoephedrine (Systemic).
Dextromethorphan-containing—See Dextromethorphan (Systemic) .
Opioid (narcotic) antitussive–containing—See Opioid (Narcotic) Analgesics (Systemic) .
Expectorant-containing—See:
• Guaifenesin (Systemic).
Analgesic-containing—See:
• Acetaminophen (Systemic).
• Acetaminophen and Salicylates (Systemic).
• Salicylates (Systemic).
Homatropine-containing—See Anticholinergics/Antispasmodics (Systemic) .
Precautions to Consider
Antihistamine-containing—See Antihistamines (Systemic) .
Antihistamine- and decongestant-containing—See Antihistamines and Decongestants (Systemic) .
Decongestant-containing—See:
• Ephedrine in Bronchodilators, Adrenergic (Systemic) .
Note: Products containing phenylpropanolamine were removed from the U.S. and Canadian Markets in November 2000.{61}
• Pseudoephedrine (Systemic).
Dextromethorphan-containing—See Dextromethorphan (Systemic) .
Opioid (narcotic) antitussive–containing—See Opioid (Narcotic) Analgesics (Systemic) .
Expectorant-containing—See:
• Guaifenesin (Systemic).
Analgesic-containing—See:
• Acetaminophen (Systemic).
• Acetaminophen and Salicylates (Systemic).
• Salicylates (Systemic).
Homatropine-containing—See Anticholinergics/Antispasmodics (Systemic) .
Laboratory value alterations
Table 1. Laboratory value alterations
| The following have been selected on the basis of their potential clinical significance (possible effect in parentheses where appropriate)—not necessarily inclusive (» = major clinical significance): | Legend: I=Antihistamine-containing II=Decongestant-containing III=Antitussive-containing IV=Expectorant-containing V=Analgesic-containing |
||||
|---|---|---|---|---|---|
| I |
II |
III |
IV |
V |
|
| With diagnostic test results |
|||||
| Copper sulfate urine sugar tests (false-positive test results may occur with chronic use of salicylates in doses equivalent in salicylate content to 2.4 grams or more of aspirin a day) |
 |
||||
| Gastric emptying studies (opioids delay gastric emptying, thereby invalidating test results) |
|
||||
| Gerhardt test for urine aceto-acetic acid (aspirin or sodium salicylate may cause interference because reaction with ferric chloride produces a reddish color that persists after boiling) |
|
||||
| Glucose, blood (acetaminophen may cause falsely decreased blood glucose values when measured by the glucose oxidase/peroxidase method but probably not when measured by the hexokinase/glucose-6-phosphate dehydrogenase [G6PD] method) |
|||||
| (values may be falsely increased when certain instruments are used in glucose analysis if high acetaminophen concentrations are present; consult manufacturer's instruction manual) |
|
||||
| Glucose enzymatic urine sugar tests (false-negative test results may occur with chronic use of salicylates in doses equivalent in salicylate content to 2.4 grams or more of aspirin a day) |
|
||||
| Hepatobiliary imaging using technetium Tc 99m disofenin, technetium Tc 99m lidofenin, technetium Tc 99m mebrofenin (delivery of these technetium Tc 99m–labeled radiopharmaceuticals to the small bowel may be prevented because opioids may cause constriction of the sphincter of Oddi and increased biliary tract pressure; these actions result in delayed visualization and thus resemble obstruction of the common bile duct) |
|
||||
| 5-hydroxyindoleacetic acid (5-HIAA), urine (urinary determinations may be falsely increased when nitrosonaphthol reagent is used because of color interference by guaifenesin metabolites) {15} {16} (acetaminophen may cause false-positive results in qualitative screening tests using nitrosonaphthol reagent; the quantitative test is unaffected) |
|||||
| (aspirin may alter results when fluorescent method is used) |
|
||||
| Pancreatic function determinations using bentiromide (administration of acetaminophen prior to the bentiromide test will invalidate test results because acetaminophen is also metabolized to an arylamine and will thus increase the apparent quantity of para-aminobenzoic acid [PABA] recovered; it is recommended that acetaminophen be discontinued at least 3 days prior to administration of bentiromide) |
|
||||
| Skin tests using allergen extracts (antihistamines contained in these combinations may inhibit the cutaneous histamine response thus producing false-negative results; it is recommended that antihistamine-containing medication be discontinued at least 72 hours before testing begins) |
|
||||
| Thyroid function tests (iodides may alter the results of these tests, and a high intake of inorganic iodides has also been shown to interfere with determination of protein bound iodine [PBI]; these effects have not been reported with iodinated glycerol in usual recommended doses, but they should be kept in mind for patients receiving prolonged therapy) |
|
||||
| Uric acid, serum (acetaminophen may cause falsely increased values when the phosphotungstate uric acid test method is used) |
|
||||
| Vanillylmandelic acid (VMA), urine (guaifenesin or its metabolites may cause color interference with urinary determinations) {15} (values may be falsely increased or decreased by salicylates, depending on the method used) |
|
||||
| With physiology/laboratory test values |
|||||
| Amylase activity, plasma, and Lipase activity, plasma (may be increased because opioids can cause contractions of the sphincter of Oddi and increased biliary tract pressure; the diagnostic utility of determinations of these enzymes may be compromised for up to 24 hours after the medication has been given) |
|
||||
| Bilirubin, serum, and Lactate dehydrogenase (LDH), serum, and Prothrombin time and Transaminase, serum (prothrombin time and concentrations of bilirubin, LDH, and transaminase may be increased indicating acetaminophen-induced hepatotoxicity, especially in alcoholics, patients taking hepatic enzyme–inducing agents, or those with pre-existing hepatic disease, when single toxic doses [>8–10 grams] are taken or with prolonged use of lower doses [>3–5 grams a day]) |
|
||||
| Bleeding time (may be prolonged by aspirin for 4 to 7 days because of suppressed platelet aggregation; as little as 40 mg of aspirin affects platelet function for at least 96 hours following administration; however, clinical bleeding problems have not been reported with small doses [150 mg or less]) |
|
||||
| Platelet aggregation (may be transiently decreased by guaifenesin; however, effects on bleeding time are unlikely) |
|
||||
| Potassium, serum (concentrations may be decreased by aspirin or sodium salicylate because of increased potassium excretion caused by direct effect on renal tubules) |
|
||||
| Protirelin-induced thyroid-stimulating hormone (TSH) release (TSH response to protirelin may be decreased by aspirin in doses of 2 to 3.6 grams daily; peak TSH concentrations occur at the same time after administration but are reduced) |
|
||||
| Uric acid, serum (concentrations may be increased with doses of aspirin or sodium salicylate producing plasma salicylate concentrations below 100 to 150 mcg per mL or decreased with doses producing plasma salicylate concentrations above 100 to 150 mcg per mL) |
|
||||
Side/Adverse Effects
Antihistamine-containing—See Antihistamines (Systemic) .
Antihistamine- and decongestant-containing—See Antihistamines and Decongestants (Systemic) .
Decongestant-containing—See:
• Ephedrine in Bronchodilators, Adrenergic (Systemic) .
• Pseudoephedrine (Systemic).
Dextromethorphan-containing—See Dextromethorphan (Systemic) .
Opioid (narcotic) antitussive–containing—See Opioid (Narcotic) Analgesics (Systemic) .
Expectorant-containing—See:
• Guaifenesin (Systemic).
Analgesic-containing—See:
• Acetaminophen (Systemic).
• Acetaminophen and Salicylates (Systemic).
• Salicylates (Systemic).
Homatropine-containing—See Anticholinergics/Antispasmodics (Systemic) .
Patient Consultation
Note: Products containing phenylpropanolamine were removed from the U.S. and Canadian Markets in November 2000.
Table 2. Patient Consultation
| As an aid to patient consultation, refer to Advice for the Patient, Cough/Cold Combinations (Systemic) . In providing consultation, consider emphasizing the following selected information (» = major clinical significance): |
Legend I=Antihistamine-containing II=Decongestantcontaining |
III=Opioid (Narcotic) Antitussive–containing IV=Non-opioid Anti- tussive–containing V=Expectorant-containing |
VI=Analgesic- containing 1 VII=Anticholi- nergic containing |
||||
|---|---|---|---|---|---|---|---|
| I |
II |
III |
IV |
V |
VI |
VII |
|
| Before using this medication » Conditions affecting use, especially: |
|||||||
| Sensitivity to any of the medications in the combination being taken |
|
|
|
|
|
|
|
| Pregnancy— Concern for the fetus or newborn infant, especially with high-dose and/or long-term usage |
|
|
|
|
|
|
|
| Physical dependence in the neonate possible with regular use |
|
||||||
| Iodinated glycerol not recommended, because may induce fetal goiter |
|
||||||
| Breast-feeding— Antihistamines may cause excitement or irritability in nursing infant |
|
||||||
| High risk for infants from sympathomimetic amines |
|
||||||
| Concern with high doses and chronic use because of high salicylate intake by infant |
2 |
||||||
| Iodinated glycerol not recommended, because may induce skin rash and thyroid suppression in nursing infant |
|
||||||
| Use in children— Increased susceptibility to anticholinergic effects |
|
|
|||||
| Increased susceptibility to vasopressor effects of sympathomimetic amines |
|
||||||
| Paradoxical reaction (hyperexcitability) |
|
|
|
||||
| Increased susceptibility to toxic effects of salicylates, especially if fever and dehydration present |
2 |
||||||
| Possible association between aspirin usage and Reye's syndrome |
2 |
||||||
| Increased susceptibility to goitrogenic effects of iodides |
3 |
||||||
| Increased susceptibility to respiratory depressant effects of opioids in children up to 2 years of age |
|
||||||
| Use in the elderly— Anticholinergic effects more likely to occur |
|
|
|||||
| Increased sensitivity to CNS and vasopressor effects of sympathomimetic amines |
|
||||||
| Increased susceptibility to toxic effects of salicylates |
2 |
||||||
| Increased susceptibility to respiratory depressant effects of opioids |
|
||||||
| Other medications, especially: Alcohol |
|
|
4 |
|
|||
| Alkalizers, urinary |
2 |
||||||
| Anticholinergics |
|
|
|||||
| Anticoagulants |
2 |
||||||
| Antidepressants, tricyclic |
|
|
|||||
| Antidiabetic agents, oral |
2 |
||||||
| Antihypertensives |
|
||||||
| Anti-inflammatory drugs, nonsteroidal |
2 |
||||||
| Antithyroid agents |
3 |
||||||
| Beta-adrenergic blocking agents, oral |
|
||||||
| CNS depressants |
|
4 |
|||||
| CNS stimulants |
|
||||||
| Heparin |
2 |
||||||
| Lithium |
3 |
||||||
| Methotrexate |
2 |
||||||
| Monoamine oxidase (MAO) inhibitors |
|
|
4 |
|
|||
| Platelet aggregation inhibitors |
2 |
||||||
| Probenecid |
2 |
||||||
| Rauwolfia alkaloids |
|
||||||
| Sulfinpyrazone |
2 |
||||||
| Thrombolytic agents |
2 |
||||||
| Vancomycin |
|
||||||
| Zidovudine |
|
||||||
| Other medical problems, especially: |
|||||||
| Alcoholism, active 9 |
8 |
||||||
| Asthma |
|
4 |
2 |
||||
| Bleeding problems |
2 |
||||||
| Cardiovascular disease |
|
||||||
| Diabetes |
|
||||||
| Diarrhea |
|
||||||
| Gastritis or peptic ulcer |
2 |
||||||
| Glaucoma |
|
|
|||||
| Hypertension |
|
||||||
| Inflammatory bowel disease |
|
||||||
| Prostatic hypertrophy |
|
|
|||||
| Thyroid disease |
|
||||||
| Proper use of this medication Taking with food, water, or milk to minimize gastric irritation |
|
2 |
|||||
| » Importance of drinking a glass of water after each dose of medication to help loosen mucus in lungs |
|
|
|
|
|
|
|
| » Importance of not taking more medication than the amount recommended |
|
|
5 |
|
|
5 |
|
| Swallowing extended-release dosage form whole |
|
|
|
|
|
|
|
| » Not taking combinations containing aspirin if a strong vinegar-like odor is present |
|
||||||
| Missed dose: If on scheduled dosing regimen—Taking as soon as possible; not taking if almost time for next dose; not doubling doses |
|
|
|
|
|
|
|
| » Proper storage |
|
|
|
|
|
|
|
| Precautions while using this medication » Checking with physician if symptoms persist after medication has been used for 7 days or if high fever, skin rash, or continuing headache is present with cough |
|
|
|
|
|
|
|
| Possible interference with skin tests using allergens; need to inform physician of use of medication |
|
||||||
| » Avoiding use of alcohol or other CNS depressants |
|
|
|||||
| » Caution if drowsiness or dizziness occurs |
|
6 |
|||||
| Lying down if nausea occurs |
|
||||||
| Possible dryness of mouth; using sugarless candy or gum, ice, or saliva substitute for relief; checking with physician or dentist if dry mouth continues for more than 2 weeks |
|
|
|||||
| May mask ototoxic effects of large doses of salicylates |
|
||||||
| » Caution if taking appetite suppressants |
|
||||||
| » Possible insomnia; taking the medication a few hours before bedtime |
7 |
||||||
| » Caution during exercise and hot weather; overheating may result in heat stroke |
|
||||||
| Caution when getting up suddenly from a lying or sitting position |
|
||||||
| Need to inform physician or dentist of use of medication if any kind of surgery (including dental surgery) or emergency treatment is required |
|
|
|||||
| » Caution if other medications containing acetaminophen, aspirin, or other salicylates (including diflunisal) are used |
|
||||||
| Diabetics: Salicylates present in some of these combinations may cause false urine sugar tablet test results with use of larger doses |
|
||||||
| Not taking products containing aspirin for 5 days prior to any kind of surgery, unless otherwise directed by physician |
|
||||||
| Side/adverse effects Signs of potential side effects, especially: Allergic reactions |
|
|
|
|
|
|
|
| Anemia |
|
||||||
| Anticholinergic effects |
|
|
|||||
| Blood dyscrasias |
|
||||||
| Gastrointestinal irritation or bleeding |
2 |
||||||
| Jaundice |
8 |
||||||
| Parotitis, acute |
3 |
||||||
2 Applies to salicylates only, particularly aspirin.
3 Applies to iodides (e.g., calcium iodide, iodinated glycerol, potassium iodide) only.
4 Applies to dextromethorphan.
5 Danger of overdose of acetaminophen, salicylates, or opioid (narcotic) antitussives; also, acetaminophen may cause liver damage with long-term or high-dose use.
6 In addition to drowsiness and dizziness, a false sense of well-being may also occur with the opioid (narcotic) antitussives.
7 The possibility of insomnia may be minimized with preparations containing an antihistamine or an opioid (narcotic) antitussive.
8 Applies to acetaminophen only.
9 Caution should be exercised whether alcoholism is active or in remission with all alcohol-containing products.
COUGH COLD COMBINATIONS
Oral Dosage Forms
Note: Products containing phenylpropanolamine were removed from the U.S. and Canadian Markets in November 2000.{61}
Table 3. Oral Dosage Forms
Note: Content per capsule, tablet, or 5 mL, unless otherwise stated.
| Brand or generic name [availability] |
Antihistamines |
Decongestants |
Antitussives |
Expec- torants |
Analgesics |
Other content information as per product label |
Usual adult and adolescent dose prn ‡ |
Usual pediatric dose prn |
Packaging, storage and auxiliary labeling § |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Opioid |
Non-opioid |
|||||||||
| Alka-Seltzer Plus Cold and Cough Effervescent Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCL 5 mg |
Dextrometh- orphan HBr 10 mg |
Phenylalanine 11.2 mg Sodium 507 mg |
a, e |
|||||
| Alka-Seltzer Plus Cold & Cough Medicine Liqui-Gels Capsules (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 325 mg |
6–12 yrs: 1 cap q 4 hr (max 4 caps/day) |
a, e |
||||
| Alka-Seltzer Plus Flu & Body Aches Medicine Liqui-Gels Capsules (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 250 mg |
2 caps q 4 hr (max 8 caps/day) |
6–12 yrs: 1 cap q 4 hr (max 4 caps/day) |
a, e |
||||
| Alka-Seltzer Plus Night Time Cold Effervescent Tablets (OTC) [U.S.] |
Doxylamine succinate 6.25 mg |
Phenylephrine HCL 5 mg |
Dextrometh- orphan HBr 10 mg |
Aspirin 500 mg |
Sodium 506 mg Phenylalanine 16.2 mg |
a, e |
||||
| Alka-Seltzer Plus Night-Time Cold Liqui-Gels Capsules (OTC) [U.S.] |
Doxylamine succinate 6.25 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
Alcohol free |
b, e |
||||
| Ami-Tex LA Extended-release Tablets (Rx) [U.S.] |
Phenylephrine HCl 30 mg |
Guaifenesin 600 mg |
Scored |
1 tab q 12 hr |
6–12 yrs: 1/2 tab q 12 hr |
a1 , d |
||||
| Anatuss LA Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 400 mg |
Scored |
1 tab q 12 hr |
6–12 yrs: 1/2 tab q 12 hr |
b |
||||
| Anti-Tuss DM Expectorant Oral Solution (OTC) [U.S.] |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 100 mg |
Alcohol 1.4% |
b, c |
||||||
| Benylin DM-D Syrup (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol free Sodium 19 mg Sugar free |
10 mL q 6 hr (max 4 doses/day) |
2–5 yrs: 2.5 mL, 6–11 yrs: 5 mL, q 6 hr (max 4 doses/day) |
a |
||||
| Benylin DM-D for Children Syrup (OTC) [Canada] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free Sodium 11.04 mg Sugar free |
2–5 yrs: 5 mL, 6–12 yrs: 10 mL, q 6 hr |
a |
|||||
| Benylin DM-D-E Syrup (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 100 mg |
Alcohol 5% Sodium 20.6 mg Sugar free |
10 mL q 6 hr (max 4 doses/day) |
2–5 yrs: 2.5 mL, 6–11 yrs: 5 mL, q 6 hr (max 4 doses/day) |
a |
|||
| Benylin DM-D-E Extra Strength Syrup (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 200 mg |
Alcohol 5% Sodium 19.6 mg Sugar free |
10 mL q 6 hr (max 4 doses/day) |
Not recommended |
a |
|||
| Benylin DM-E Syrup (OTC) [Canada] |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 100 mg |
Alcohol 5% Sodium 20.6 mg Sugar free |
10 mL q 6 hr (max 4 doses/day) |
2–5 yrs: 2.5 mL, 6–11 yrs: 5 mL, q 6 hr (max 4 doses/day) |
a |
||||
| Benylin DM-E Extra Strength Syrup (OTC) [Canada] |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 200 mg |
Alcohol Sodium 19.6 mg Sugar free |
10 mL q 6 hr (max 4 doses/day) |
Not recommended |
a |
||||
| Benylin Expectorant Oral Solution (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free |
b, c |
||||||
| Benylin 4 Flu Oral Solution (OTC) [Canada] |
Pseudoephedrine HCl 30 mg/15 mL |
Dextrometh- orphan HBr 15 mg/15 mL |
Guaifenesin 100 mg/ 15 mL |
Acetami- nophen 500 mg/ 15 mL |
Alcohol 5% Sugar free |
30 mL q 6 hr (max 4 doses/day) |
Not recommended |
a, c |
||
| Bromfed-DM Syrup (Rx) [U.S.] |
Brompheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextromethorphan HBr 10 mg |
Alcohol free |
10 mL q 4 hr (max 6 doses/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4 hr (max 6 doses/day) |
a, c, d, e |
|||
| Broncholate Syrup (Rx) [U.S.] |
Ephedrine HCl 6.25 mg |
Guaifenesin 100 mg |
10–20 mL q 4 hr |
2–6 yrs: 2.5–5 mL, 6–12 yrs: 5–10 mL, q 4 hr |
a, c, d |
|||||
| Brontex Oral Solution (Schedule V) [U.S.] |
Codeine PO 4 2.5 mg |
Guaifenesin 75 mg |
20 mL q 4 hr (max 120 mL/day) |
6–12 yrs: 10 mL q 4 hr |
b, e, f |
|||||
| Tablets (Schedule III) [U.S.] |
Codeine PO 4 10 mg |
Guaifenesin 300 mg |
1 tab q 4 hr |
Recommended for use in pediatric patients 12 years of age and older |
b, e, f |
|||||
| Calmydone Syrup (N) [Canada] |
Doxylamine succinate 1.2 mg/mL |
Etafedrine HCl 3.33 mg/mL |
Hydrocodone bitartrate 0.33 mg/mL |
Alcohol 5% Sodium citrate 40 mg/mL |
a, e, f |
|||||
| Calmylin #2 Syrup (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol free Sugar free |
5–10 mL q 6–8 hr |
2–5 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6–8 hr |
a, c, e |
||||
| Calmylin #3 Syrup (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 100 mg |
Alcohol 5% Sugar free |
10 mL q 6–8 hr |
2–5 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6–8 hr |
a, c, e |
|||
| Calmylin #4 Syrup (OTC) [Canada] |
Diphenhydramine HCl 12.5 mg |
Dextrometh- orphan HBr 15 mg |
Ammonium chloride † 125 mg |
Alcohol 5% |
5–10 mL q 6–8 hr |
2–3 yrs: 1.25 mL, 4–12 yrs: 2.5–5 mL, q 6–8 hr |
a, c, e |
|||
| Calmylin Cough & Flu Syrup (OTC) [Canada] |
Pseudoephedrine HCl 30 mg/ 15 mL |
Dextrometh- orphan HBr 15 mg/15 mL |
Guaifenesin 100 mg/ 15 mL |
Acetamin- ophen 325 mg/ 15 mL |
Alcohol free Sugar free |
15–30 mL q 6–8 hr (max 120 mL/day) |
Not recommended |
a, c |
||
| Calmylin DM-D-E Extra Strength Syrup (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 200 mg |
Alcohol 5% Sugar free |
10 mL q 6 hr |
Not recommended |
a, c |
|||
| Calmylin Original with Codeine Syrup (N) [Canada] |
Diphenhydramine HCl 12.5 mg |
Codeine PO 4 3.33 mg |
Ammonium chloride † 125 mg |
Alcohol 2.9% |
5–10 mL q 3–4 hr |
b, c, e, f |
||||
| Calmylin Pediatric Syrup (OTC) [Canada] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free Sugar free |
1–2 yrs: 2.5 mL 2–6 yrs: 5 mL, 6–12 yrs: 10 mL, q 6–8 hr |
a, c |
|||||
| Carbinoxamine Compound-Drops Oral Solution (Rx) [U.S.] |
Carbinoxamine maleate 2 mg/mL |
Pseudoephedrine HCl 25 mg/mL |
Dextrometh- orphan HBr 4 mg/mL |
Alcohol <0.2% |
1–18 mos: 0.25–1 mL q 6 hr |
b, c, e |
||||
| Cardec DM Syrup (Rx) [U.S.] |
Carbinoxamine maleate 4 mg |
Pseudoephedrine HCl 60 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol <0.6% |
5 mL q 6 hr |
b, c, e |
||||
| Cheracol Syrup (N) [Canada] |
Codeine PO 4 10 mg |
Ammonium Cl † 91 mg, Guaifenesin 100 mg |
Alcohol 4.75% |
10 mL q 4–6 hr |
6–12 yrs: 5 mL q 4–6 hr |
a, d, e, f |
||||
| Children's Tylenol Cold Plus Cough Multi Symptom Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 1 mg |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 5 mg |
Acetamin- ophen 160 mg |
Alcohol free |
Intended for pediatric use |
2–5 yrs: 5 mL, 6–11 yrs: 10 mL, q 4–6 hr (max 4 doses/day) |
b, c, e |
||
| Chewable Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 0.5 mg |
Pseudoephedrine HCl 7.5 mg |
Dextrometh- orphan HBr 2.5 mg |
Acetamin- ophen 80 mg |
Intended for pediatric use |
2–5 yrs: 2 tabs, 6–11 yrs: 4 tabs, q 4–6 hr (max 4 doses/day) |
b, e, i |
|||
| Chlorgest-HD Oral Solution (Schedule III) [U.S.] |
Chlorpheniramine maleate 4 mg |
Phenylephrine HCl 5 mg |
Hydrocodone bitartrate 1.67 mg |
Alcohol free Sugar free |
10 mL q 6–8 hr |
b, c, e, f |
||||
| CoActifed Oral Solution (N) [Canada] |
Triprolidine HCl 2 mg |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Alcohol free |
10 mL q 4–6 hr |
<6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4–6 hr |
b, c, d, e, f |
|||
| Tablets (N) [Canada] |
Triprolidine HCl 4 mg |
Pseudoephedrine HCl 60 mg |
Codeine PO 4 20 mg |
Scored |
1 tab q 4–6 hr |
<6 yrs: See CoActifed Syrup 6–12 yrs: 1/2 tab q 4–6 hr |
b, d, e, f |
|||
| CoActifed Expectorant Oral Solution (N) [Canada] |
Triprolidine HCl 2 mg |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol free |
10 mL q 4–6 hr |
<6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4–6 hr |
b, c, d, e, f |
||
| Co-Apap Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
2 tabs q 6 hr |
6–12 yrs: 1 tab q 6 hr |
b, e |
|||
| Comtrex Daytime Maximum Strength Cold, Cough and Flu Relief Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
Available in a dual package that also contains Comtrex Nighttime Maximum Strength Cold, Cough and Flu Relief |
2 tabs q 6 hr (max 4 tabs/day) |
b |
||||
| Comtrex Daytime Maximum Strength Cold and Flu Relief Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
Available in a dual package that also contains Comtrex Nighttime Maximum Strength Cold and Flu Relief |
2 tabs q 6 hr (max 4 tabs/day) |
b |
||||
| Comtrex Multi-Symptom Maximum Strength Non-Drowsy Caplets Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
2 tabs q 6 hr (max 8 tabs/day) |
Intended for adult use |
b |
||||
| Comtrex Nighttime Maximum Strength Cold and Flu Relief Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
Available in a dual package that also contains Comtrex Daytime Maximum Strength Cold and Flu Relief |
2 tabs hs |
b, e |
|||
| Congestac Caplets Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 60 mg |
Guaifenesin 400 mg |
1 tab q 4 hr (max 4 tabs/day) |
b |
||||||
| Contac Cold/Flu Day Caplets Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 60 mg |
Dextrometh- orphan HBr 30 mg |
Acetamin- ophen 650 mg |
Available in a dual package that also contains Contac Cold/Flu Night Caplets |
1 tab q 6 hr (max 4 tabs/day of any combination of Day or Night caplets) |
b |
||||
| Contac Severe Cold & Flu Caplets Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
2 tabs q 6 hr (max 8 tabs/day) |
b, c, e |
||||
| Coristex-DH Oral Solution (N) [Canada] |
Phenylephrine HCl 20 mg |
Hydrocodone bitartrate 5 mg |
Alcohol 4.25% Sucrose 33% |
5 mL q 4 hr |
6–12 yrs: 2.5 mL q 4 hr |
a, c, d, e, f |
||||
| Coristine-DH Oral Solution (N) [Canada] |
Phenylephrine HCl 10 mg |
Hydrocodone bitartrate 1.7 mg |
Alcohol 4.3% Sucrose 33% |
10 mL q 4 hr |
6 mos–1 yr: 1.25–2.5 mL, 1–12 yrs: 2.5–5 mL, q 4 hr |
a, c, d, e, f |
||||
| Cotridin Oral Solution (N) [Canada] |
Triprolidine HCl 2 mg |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Alcohol free |
10 mL q 4–6 hr (max 4 doses/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4–6 hr (max 4 doses/day) |
a, d, e, f |
|||
| Cotridin Expectorant Oral Solution (N) [Canada] |
Triprolidine HCl 2 mg |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol free |
10 mL q 6 hr (max 4 doses/day) |
2–5 yrs: 2.5 mL, 6–11 yrs: 5 mL, q 6 hr (max 4 doses/day) |
a, d, e, f |
||
| Co-Tuss V Oral Solution (Schedule III) [U.S.] |
Hydrocodone bitartrate 5 mg |
Guaifenesin 100 mg |
5 mL q 4 hr |
b, c, e, f |
||||||
| Deconsal II Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 60 mg |
Guaifenesin 600 mg |
Scored |
1–2 tabs q 12 hr (max 4 tabs/day) |
2–6 yrs: 1/2 tab (max 1 tab/day), 6–12 yrs: 1 tab (max 2 tabs/day), q 12 hr |
b |
||||
| Despec Oral Solution (Rx) [U.S.] |
Phenylephrine HCl 5 mg, |
Guaifenesin 100 mg |
Alcohol 5% |
b, c |
||||||
| Despec-SR Caplets Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120mg |
Guaifenesin 800 mg |
Scored |
a, d |
||||||
| Dimetane Expectorant-C Oral Solution (N) [Canada] |
Brompheniramine maleate 2 mg |
Phenylephrine HCl 5 mg, |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 3.5% |
a, c, d, e, f |
||||
| Dimetane Expectorant-DC Oral Solution (N) [Canada] |
Brompheniramine maleate 2 mg |
Phenylephrine HCl 5 mg, |
Hydrocodone bitartrate 1.8 mg |
Guaifenesin 100 mg |
Alcohol 3.5% |
b, c, e, f |
||||
| Dimetapp-C Syrup (N) [Canada] |
Brompheniramine maleate 2 mg |
Phenylephrine HCl 5 mg, |
Codeine PO 4 10 mg |
Alcohol Sodium 3.1 mg Sugar free |
a |
|||||
| Donatussin Syrup (Rx) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 10 mg |
Dextrometh- orphan HBr 7.5 mg |
Guaifenesin 100 mg |
Alcohol free |
5 mL q 4–6 hr (max 6 doses/day) |
2–6 yrs: 1.25 mL, 6–12 yrs: 2.5 mL, q 4–6 hr |
b, c, e |
||
| Donatussin DC Syrup (Schedule III) [U.S.] |
Phenylephrine HCl 7.5 mg |
Hydrocodone bitartrate 2.5 mg |
Guaifenesin 50 mg |
Alcohol free |
10 mL q 4–6 hr (max 6 doses/day) |
3–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4-6 hr |
b, c, d, e, f |
|||
| Duratuss Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 600 mg |
Scored Dye free Film-coated |
1 tab q 12 hr |
6–12 yrs: 1/2 tab q 12 hr |
b |
||||
| Duratuss HD Elixir (Schedule III) [U.S.] |
Pseudoephedrine HCl 30 mg |
Hydrocodone bitartrate 2.5 mg |
Guaifenesin 100 mg |
Alcohol 5% |
10 mL q 4–6 hr (max 4 doses/day) |
6–12 yrs: 5 mL q 4–6 hr (max 4 doses/day) |
b, c, e, f |
|||
| ED-TLC Oral Solution (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 5 mg |
Hydrocodone bitartrate 1.67 mg |
10 mL q 6–8 hr |
6–12 yrs: 5 mL q 6–8 hr |
b, c, e, f |
||||
| ED Tuss HC Oral Solution (Schedule III) [U.S.] |
Chlorpheniramine maleate 4 mg |
Phenylephrine HCl 10 mg |
Hydrocodone bitartrate 2.5 mg |
Alcohol 5% |
5 mL q 6 hr |
2–6 yrs: 1.25 mL, 6–12 yrs: 2.5 mL, q 4–6 hr |
b, c, e, f |
|||
| Endagen-HD Oral Solution (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 5 mg |
Hydrocodone bitartrate 1.7 mg |
Alcohol free |
10 mL q 6–8 hr |
6–12 yrs: 5 mL q 6–8 hr |
b, c, e, f |
|||
| Endal Expectorant Syrup (Schedule V) [U.S.] |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 5% Sugar free Dye free |
5–10 mL q 6–8 hr |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6–8 hr |
b, c, e, f |
||||
| Entex LA Extended-release Tablets (Rx) [U.S.] |
Phenylephrine HCl 30 mg |
Guaifenesin 600 mg |
Scored |
b |
||||||
| Father John's Medicine Plus Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 1 mg |
Phenylephrine HCl 2.5 mg |
Dextrometh- orphan HBr 7.5 mg |
Guaifenesin 30 mg, Ammonium Cl † 83.3 mg |
Alcohol free |
5–10 mL q 3–4 hr |
2–6 yrs: 5 mL, 6–12 yrs: 5–10 mL, q 6–8 hr |
b, c, e |
||
| Genatuss DM Syrup (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free |
10 mL q 4 hr |
b, c |
|||||
| GP-500 Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 500 mg |
Scored |
1 tab q 12 hr |
6–12 yrs: 1/2 tab q 12 hr |
a, d |
||||
| Guaifed Extended-release Capsules (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg (extended-release) |
Guaifenesin 250 mg (immediate release) |
1 cap q 12 hr |
Pediatric strength not available |
a |
|||||
| Syrup (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Guaifenesin 200 mg |
Sugar free |
10 mL q 4–6 hr (max 4 doses/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4–6 hr (max 4 doses/day) |
b |
||||
| Guaifenex PSE 60 Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 60 mg |
Guaifenesin 600 mg |
Scored |
1–2 tabs q 12 hr (max 4 tabs/day) |
2–6 yrs: 1/2 tab (max 1 tab/day), 6–12 yrs: 1 tab (max 2 tabs/day), q 12 hr |
a, d |
||||
| Guaifenex PSE 120 Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 600 mg |
Scored |
1 tab q 12 hr |
6–12 yrs: 1/2 tab q 12 hr |
a, d |
||||
| GuaiMAX-D Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 600 mg |
Scored |
1 tab q 12 hr |
6–12 yrs: 1/2 tab q 12 hr |
b |
||||
| Guai-Vent/PSE Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 600 mg |
Scored |
1 tab q 12 hr |
6–12 yrs: 1/2 tab q 12 hr |
a2 , d |
||||
| Guiatuss A.C. Syrup USP (Schedule V) [U.S.] |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 3.5% |
10 mL q 4 hr |
2–6 yrs: 1.25–2.5 mL, 6–12 yrs: 2.5–5 mL, q 4–6 hr |
a, d, e, f |
||||
| Guiatuss CF Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 30/5 mg/mL |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free |
b, c |
|||||
| Guiatuss DAC Oral Solution (Schedule V) [U.S.] |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 1.9% |
10 mL q 4 hr (max 40 mL/day) |
b, c, e, f |
||||
| Guiatuss PE Syrup (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Guaifenesin 100 mg |
Alcohol free |
10 mL q 4 hr (max 40 mL/day) |
b, c |
|||||
| Histenol Tablets (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 325 mg |
1–2 tabs q 4 hr (max 8 tabs/day) |
6–12 yrs: 1/2–1 tab q 4 hr |
a |
||||
| Histinex HC Syrup (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 5 mg |
Hydrocodone bitartrate 2.5 mg |
Alcohol free Sugar free |
10 mL q 4 hr (max 40 mL/day) |
6–12 yrs: 5 mL q 4 hr (max 20 mL/day) |
a, d, e, f |
|||
| Histinex PV Syrup (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Hydrocodone bitartrate 2.5 mg |
Alcohol free Sugar free |
10 mL q 4–6 hr (max 4 doses/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4–6 hr (max 4 doses/day) |
a, d, f |
|||
| Hycodan Syrup (Schedule III) [U.S.] |
Hydrocodone bitartrate 5 mg |
Homatropine MBr 1.5 mg ** |
5 mL q 4–6 hr (max 30 mL/day) |
6–12 yrs: 2.5 mL q 4–6 hr (max 15 mL/day) |
b, c, e, f |
|||||
| Syrup (N) [Canada] |
Hydrocodone bitartrate 5 mg |
Alcohol free |
5 mL at intervals ³4 hr (max 30 mL/day) |
<2 yrs: 1.25 mL (max 7.5 mL/day), 2–12 yrs: 2.5 mL (max 15 mL/day), at intervals ³4 hr |
b, c, d, e, f |
|||||
| Tablets (N) [Canada] |
Hydrocodone bitartrate 5 mg |
Scored |
1 tab at intervals ³4 hr (max 6 tabs/day) |
<2 yrs: 1/4 tab (max 11/2 tabs/day), 2–12 yrs: 1/2 tab (max 3 tabs/day), at intervals ³4 hr. See also Hycodan Syrup |
b, d, e, f |
|||||
| Hycomine Compound Tablets (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 10 mg |
Hydrocodone bitartrate 5 mg |
Acetamin- ophen 250 mg |
Caffeine 30 mg Scored |
1 tab 4 times/day (at intervals ³4 hr) |
6–12 yrs: 1/2 tab 4 times/day (at intervals ³4 hr) |
b, e, f |
||
| Hydrocodone and Homatropine * Syrup (Schedule III) [U.S.] |
Hydrocodone bitartrate 5 mg |
Homatropine MBr 1.5 mg ** |
5 mL q 4–6 hr |
<2 yrs: 1.25 mL, 2–12 yrs: 2.5 mL, q 4–6 hr |
b, c, d, e, f |
|||||
| Hydropane Syrup (Schedule III) [U.S.] |
Hydrocodone bitartrate 5 mg |
Homatropine MBr 1.5 mg ** |
5 mL q 4–6 hr |
<2 yrs: 1.25 mL, 2–12 yrs: 2.5 mL, q 4–6 hr |
b, c, d, e, f |
|||||
| Iobid DM Extended-release Tablets (Rx) [U.S.] |
Dextrometh- orphan HBr 30 mg |
Guaifenesin 600 mg |
1–2 tabs q 12 hr (max 4 tabs/day) |
2–6 yrs: 1/2 tab, 6–12 yrs: 1 tab, q 12 hr (max 2 doses/day) |
a, d |
|||||
| Iodal HD Oral Solution (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 5 mg |
Hydrocodone bitartrate 1.67 mg |
10 mL q 4 hr (max 40 mL/day) |
6–12 yrs: 5 mL q 4 hr (max 20 mL/day) |
a, d, e, f |
||||
| Iosal II Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 60 mg |
Guaifenesin 600 mg |
1–2 tabs q 12 hr (max 4 tabs/day) |
2–5 yrs: 1/2 tab, 6–12 yrs: 1 tab, q 12 hr (max 2 doses/day) |
a, d |
|||||
| Iotussin HC Oral Solution (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 5 mg |
Hydrocodone bitartrate 2.5 mg |
10 mL q 4 hr (max 40 mL/day) |
6–12 yrs: 5 mL q 4 hr (max 20 mL/day) |
a, d, e, f |
||||
| Kolephrin/DM Cough and Cold Medication Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 325 mg |
2 tab q 4–6 hr (max 8 tabs/day) |
6–12 yrs: 1 tab q 4–6 hr (max 4 tabs/day) |
b, e |
|||
| Kolephrin GG/DM Oral Solution (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 150 mg |
Alcohol free |
10 mL q 4 hr |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4 hr |
b, c |
||||
| Kwelcof Liquid Oral Solution (Schedule III) [U.S.] |
Hydrocodone bitartrate 5 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free Dye free |
5 mL q 4–6 hr |
2–12 yrs: 2.5–5 mL q 4–6 hr |
b, c, e, f |
||||
| Mapap Cold Formula Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
2 tabs q 6 hr |
6–12 yrs: 1 tab q 6 hr |
b, e |
|||
| Marcof Expectorant Syrup (Schedule III) [U.S.] |
Hydrocodone bitartrate 5 mg |
Potassium guaiacol- sulfonate † 350 mg |
Alcohol free Sugar free |
a, c, e, f |
||||||
| Mersyndol with Codeine Tablets (N) [Canada] |
Doxylamine succinate 5 mg |
Codeine PO 4 8 mg |
Acetamin- ophen 325 mg |
1–2 tabs q 4 hr (max 12 tabs/day) |
a, e, f |
|||||
| Nalex DH Elixir (Schedule III) [U.S.] |
Phenylephrine HCl 5 mg |
Hydrocodone bitartrate 1.67 mg |
Alcohol 5% |
10 mL q 4–6 hr (max 4 doses/day) |
2–6 yrs: 2.5–5 mL, 6–12 yrs: 5 mL, q 4–6 hr (max 4 doses/day) |
a, c, d, f |
||||
| Neo Citran DM Coughs and Colds for Oral Solution (OTC) [Canada] |
Pheniramine maleate 20 mg/ pouch |
Phenylephrine HCl 10 mg/pouch |
Dextrometh- orphan HBr 30 mg/ pouch |
Vitamin C 50 mg, Tartrazine |
1 pouch dissolved in 8 oz boiling water q 6–8 hr (max 3 pouches/day) |
e |
||||
| Novahistex DH Oral Solution (N) [Canada] |
Phenylephrine HCl 20 mg |
Hydrocodone bitartrate 5 mg |
Alcohol free |
5 mL q 4 hr |
b, c, e, f |
|||||
| Novahistex DH Expectorant Oral Solution (N) [Canada] |
Phenylephrine HCl 20 mg |
Hydrocodone bitartrate 5 mg |
Guaifenesin 200 mg |
Alcohol free Fructose 10%, Glucose 14.3% |
5 mL q 4 hr |
b, c, e, f |
||||
| Novahistine DH Oral Solution (N) [Canada] |
Phenylephrine HCl 10 mg |
Hydrocodone bitartrate 1.7 mg |
Alcohol free |
10 mL q 4 hr |
6 mos–1 yr: 1.25–2.5 mL, 1–12 yrs: 2.5–5 mL, q 4 hr |
b, c, e, f |
||||
| Novahistine DH Liquid Oral Solution (Schedule V) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Alcohol 5% |
10 mL q 4–6 hr (max 40 mL/day) |
6–12 yrs: 5 mL q 4–6 hr (max 20 mL/day) |
a, c, d, e, f |
|||
| Novahistine DM w/ Decongestant Oral Solution (OTC) [Canada] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free |
2–5 yrs: 5 mL (max 20 mL/day), 6–12 yrs: 10 mL (max 40 mL/day), q 4–6 hr |
a |
|||||
| Novahistine DM Expectorant w/ Decongestant Oral Solution (OTC) [Canada] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Guaifenesin 50 mg |
Alcohol free |
2–5 yrs: 5 mL (max 20 mL/day), 6–12 yrs: 10 mL (max 40 mL/day), q 4–6 hr |
a |
||||
| Nucofed Capsules (Schedule III) [U.S.] |
Pseudoephedrine HCl 60 mg |
Codeine PO 4 20 mg |
1 cap q 6 hr (max 4 caps/day) |
Pediatric strength not available. See Nucofed Syrup |
b, e, f |
|||||
| Syrup (Schedule III) [U.S.] |
Pseudoephedrine HCl 60 mg |
Codeine PO 4 20 mg |
Alcohol free, Sucrose 2.25 gm |
5 mL q 6 hr (max 4 doses/day) |
2–6 yrs: 1.25 mL, 6–12 yrs: 2.5 mL, q 6 hr (max 4 doses/day) |
b, c, e, f |
||||
| Nucofed Expectorant Syrup (Schedule III) [U.S.] |
Pseudoephedrine HCl 60 mg |
Codeine PO 4 20 mg |
Guaifenesin 200 mg |
Alcohol 12.5% |
5 mL q 6 hr (max 4 doses/day) |
2–6 yrs: 1.25 mL, 6–12 yrs: 2.5 mL, q 6 hr (max 4 doses/day) |
b, c, e, f |
|||
| Nucofed Pediatric Expectorant Syrup (Schedule V) [U.S.] |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 6% |
10 mL q 6 hr (max 4 doses/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6 hr (max 4 doses/day) |
a, c, e, f |
|||
| Nucotuss Expectorant Syrup (Schedule III) [U.S.] |
Pseudoephedrine HCl 60 mg |
Codeine PO 4 20 mg |
Guaifenesin 200 mg |
Alcohol 12.5% |
5 mL q 6 hr |
b, c, e, f |
||||
| Nucotuss Pediatric Expectorant Syrup (Schedule V) [U.S.] |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 6% |
2–<12 yrs: 2.5–5 mL q 6 hr |
b, c, e, f |
||||
| Nytcold Medicine Oral Solution (OTC) [U.S.] |
Doxylamine succinate 1.25 mg |
Pseudoephedrine HCl 10 mg |
Dextrometh- orphan HBr 5 mg |
Acetamin- ophen 167 mg |
Alcohol 25% |
30 mL hs or 30 mL q 6 hr |
b, c, e |
|||
| Nytime Cold Medicine Liquid Oral Solution (OTC) [U.S.] |
Doxylamine succinate 1.2 mg (7.5 mg/30 mL) |
Pseudoephedrine HCl 10 mg (60 mg/30 mL) |
Dextrometh- orphan HBr 5 mg (30 mg/ 30 mL) |
Acetamin- ophen 166.6 mg (1000 mg/ 30 mL) |
Alcohol 25% |
30 mL hs or q 6 hr |
Not recommended |
b, c, e |
||
| Ornade Expectorant Oral Solution (OTC) [Canada] |
Chlorpheniramine maleate 2 mg |
Guaifenesin 100 mg |
Alcohol 7% Sugar free |
5–10 mL q 6–8 hr |
1–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6–8 hr |
b, c, e |
||||
| Ornex Severe Cold No Drowsiness Caplets Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
2 tabs q 6 hr (max 8 tabs/day) |
b |
|||||
| PanMist-JR {58} Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 45 mg |
Guaifenesin 600 mg |
1–2 tabs q 12 hrs (max 4 tabs/day) |
6–12 yrs: 1 tab q 12 hrs (max 2 tabs/day) |
b, d |
|||||
| PediaCare Cough-Cold Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 1 mg |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 5 mg |
Alcohol free |
Intended for pediatric use |
2–3 yrs: 5 mL, 4–5 yrs: 7.5 mL, 6–8 yrs: 10 mL, 9–10 yrs: 12.5 mL, 11 yrs: 15 mL, q 4–6 hr |
b, c, e |
|||
| Chewable Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 1 mg |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 5 mg |
Phenylalanine 6 mg |
Intended for pediatric use |
2–3 yrs: 1 tab, 4–5 yrs: 11/2 tabs, 6–8 yrs: 2 tabs, 9–10 yrs: 21/2 tabs, 11 yrs: 3 tabs, q 6–8 hr |
b, e, i |
|||
| PediaCare NightRest Cough-Cold Liquid Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 1 mg |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free |
Intended for pediatric use |
2–3 yrs: 5 mL, 4–5 yrs: 7.5 mL, 6–8 yrs: 10 mL, 9–10 yrs: 12.5 mL, 11 yrs: 15 mL, q 6–8 hr |
b, c, e |
|||
| Pediacof Cough Syrup (Schedule V) [U.S.] |
Chlorpheniramine maleate 0.75 mg |
Phenylephrine HCl 2.5 mg |
Codeine PO 4 5 mg |
Potassium iodide † 75 mg |
Alcohol 5% |
Intended for pediatric use |
6 mos–1 yr: 1.25 mL, 1–3 yrs: 2.5–5 mL, 3–6 yrs: 5–10 mL, 6–12 yrs: 10 mL, q 4–6 hr |
b, c, e, f |
||
| Penntuss Oral Suspension (N) [Canada] |
Chlorpheniramine maleate 4 mg (as polistirex) |
Codeine 10 mg (as polistirex) |
Alcohol free, Sodium 4.6 mg |
10–15 mL q 12 hr (max 30 mL/day) |
2–5 yrs: 2.5 mL (max 5 mL/day), 6–12 yrs: 5 mL (max 10 mL/day), q 12 hr |
b, e, f, g |
||||
| Phanatuss Syrup (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free |
10 mL q 3–4 hr (max 8 doses/day) |
2–6 yrs: 2.5 mL q 4 hr, 6–12 yrs: 5 mL, q 3–4 hr (max 6 doses/day) |
b, c |
||||
| Pharmasave Children's Cough Syrup Syrup (OTC) [Canada] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free Sugar free |
2–5 yrs: 5 mL, 6–11 yrs: 10 mL, q 6–8 hr (max 4 doses/day) |
a, d |
|||||
| Phenameth VC Syrup [U.S.] |
Promethazine HCl 6.25 mg |
Phenylephrine HCl 5 mg |
Alcohol 7% |
5 mL q 4–6 hr |
2–6 yrs: 1.25–5 mL, 6–12 yrs: 2.5–5 mL, q 4–6 hr |
a, c, d, e, f |
||||
| Phenergan with Codeine Syrup (Schedule V) [U.S.] |
Promethazine HCl 6.25 mg |
Codeine PO 4 10 mg |
Alcohol 7% |
5 mL q 4–6 hr (max 30 mL/day) |
2–6 yrs: 1.25–2.5 mL, 6–12 yrs: 2.5–5 mL, q 4–6 hr |
a, c, d, e, f |
||||
| Phenergan with Dextromethorphan Syrup (Rx) [U.S.] |
Promethazine HCl 6.25 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol 7% |
5 mL q 4–6 hr (max 30 mL/day) |
2–6 yrs: 1.25–2.5 mL (max 10 mL/day), 6–12 yrs: 2.5–5 mL (max 20 mL/day) q 4–6 hr |
a, c, d, e |
||||
| Phenergan Expectorant w/Codeine Syrup (N) [Canada] |
Promethazine HCl 5.65 mg |
Codeine PO 4 10 mg |
Potassium guaiacol- sulfonate † 40 mg |
5–10 mL q 4–6 hr |
>2 yrs: 2.5–5 mL q 4–6 hr |
a, d, e, f, g |
||||
| Phenergan VC with Codeine Syrup (Schedule V) [U.S.] |
Promethazine HCl 6.25 mg |
Phenylephrine HCl 5 mg |
Codeine PO 4 10 mg |
Alcohol 7% |
5 mL q 4–6 hr (max 30 mL/day) |
2–6 yrs: 1.25–2.5 mL (max 6–9 mL/day), 6–12 yrs: 2.5–5 mL (max 15 mL/day), q 4–6 hr |
a, c, d, e, f |
|||
| Pneumotussin HC Syrup (Schedule III) [U.S.] |
Hydrocodone bitartrate 5 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free |
5 mL q 4 hr |
b, c, e, f |
|||||
| Poly-Histine Syrup [U.S.] |
Pheniramine maleate 4 mg Pyrilamine 4mg |
Phenyltoloxamine citrate 4mg |
Alcohol free |
b, c, e, f |
||||||
| Primatuss Cough Mixture 4 Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol 10% |
10 mL q 8 hr |
b, c, e |
|||||
| Primatuss Cough Mixture 4D Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 20 mg |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 67 mg |
Alcohol 10% |
15 mL q 6 hr |
b, c |
||||
| Profen II Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 40 mg |
Guaifenesin 800 mg |
Scored Dye free |
b |
||||||
| Promethazine and Codeine * Syrup (Schedule V) [U.S.] |
Promethazine HCl 6.25 mg |
Codeine PO 4 10 mg |
May contain alcohol |
5 mL q 4–6 hr |
2–6 yrs: 1.25–2.5 mL, 6–12 yrs: 2.5–5 mL, q 4–6 hr |
a, c, d, e, f |
||||
| Promethazine DM Oral Solution (Rx) [U.S.] |
Promethazine HCl 6.25 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol |
5 mL q 4–6 hr |
b, c, e |
|||||
| Promethazine VC w/ Codeine Oral Solution (Schedule V) [U.S.] |
Promethazine HCl 6.25 mg |
Phenylephrine HCl 5 mg |
Codeine PO 4 10 mg |
Alcohol |
5 mL q 4–6 hr |
b, c, e, f |
||||
| Prometh VC with Codeine Oral Solution (Schedule V) [U.S.] |
Promethazine HCl 6.25 mg |
Phenylephrine HCl 5 mg |
Codeine PO 4 10 mg |
Alcohol 7% |
5 mL q 4–6 hr |
2–6 yrs: 1.25–2.5 mL, 6–12 yrs: 2.5–5 mL, q 4–6 hr |
a, c, d, e, f |
|||
| Protuss-D Oral Solution (Schedule III) [U.S.] |
Pseudoephedrine HCl 30 mg |
Hydrocodone bitartrate 5 mg |
Potassium guaiacol- sulfonate † 300 mg |
Alcohol free Dye free Sugar free |
5–7.5 mL q 6 hr |
3–6 yrs: 1.25–2.5 mL, 6–12 yrs: 2.5–5 mL, q 6 hr |
a, e, f |
|||
| Pseudo-Car DM Syrup (Rx) [U.S.] |
Carbinoxamine maleate 4 mg |
Pseudoephedrine HCl 60 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol 0.19% |
5 mL q 6 hr |
18 mos–6 yrs: 2.5 mL, >6 yrs: 5 mL, q 4–6 hr |
a, c, d, e |
|||
| P-V-Tussin Syrup (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Hydrocodone bitartrate 2.5 mg |
Alcohol 5% |
10 mL q 4–6 hr (max 4 doses/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4–6 hr (max 4 doses/day) |
a, c, e, f |
|||
| Tablets (Schedule III) [U.S.] |
Pseudoephedrine 60 mg |
Hydrocodone bitartrate 5 mg |
Scored |
1 tab q 4–6 hr (max 4 doses/day) |
a, d, e, f |
|||||
| Quelidrine Cough Syrup (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Ephedrine HCl 5 mg, Phenylephrine HCl 5 mg |
Dextrometh- orphan HBr 10 mg |
Ammonium Cl † 40 mg, Ipecac fluidextract † 0.005 mL |
Alcohol 2% |
5 mL q 4–6 hr |
2–6 yrs: 1.25 mL, 6–12 yrs: 2.5 mL, q 4–6 hr |
a2 , c, e |
||
| Rentamine Pediatric Oral Suspension (Rx) [U.S.] |
Chlorpheniramine tannate 4 mg |
Ephedrine tannate 5 mg, Phenylephrine tannate 5 mg |
Carbetapen- tane tannate 30 mg |
Intended for pediatric use |
2–6 yrs: 2.5–5 mL, 6–12 yrs: 5–10 mL, q 12 hr |
b, c, e, g |
||||
| Rescon-DM Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Alcohol free Sugar free Dye free |
10 mL q 4–6 hr |
b, c, e |
||||
| Rescon-GG Oral Solution (OTC) [U.S.] |
Phenylephrine HCl 5 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free |
10 mL q 4–6 hr |
b, c |
|||||
| Respa-1st Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 60 mg |
Guaifenesin 600 mg |
Scored |
1–2 tabs q 12 hr |
6–12 yrs: 1 tab q 12 hr |
b |
||||
| Respa-DM Extended-release Tablets (Rx) [U.S.] |
Dextrometh- orphan HBr 30 mg |
Guaifenesin 600 mg |
Scored |
1–2 tabs q 12 hr |
6–12 yrs: 1 tab q 12 hr |
b |
||||
| Respaire-60 SR Extended-release Capsules (Rx) [U.S.] |
Pseudoephedrine HCl 60 mg (extended-release) |
Guaifenesin 200 mg (immediate- release) |
2 caps q 12 hr |
6–12 yrs: 1 cap q 12 hr |
b |
|||||
| Respaire-120 SR Extended-release Capsules (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg (extended-release) |
Guaifenesin 250 mg (immediate- release) |
1 cap q 12 hr |
Intended for adult use. See Respaire-60 SR |
b |
|||||
| Rhinosyn-DM Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol 1.4% Dye free |
10 mL q 6 hr |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6 hr |
b, c, e |
|||
| Rhinosyn-DMX Expectorant Syrup (OTC) [U.S.] |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 100 mg |
Alcohol 6% Dye free |
10 mL q 6 hr |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6 hr |
a, c, d |
||||
| Rhinosyn-X Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol 7.5% Dye free |
10 mL q 4 hr |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4 hr |
b, c, d |
|||
| Robafen AC Cough Syrup USP (Schedule V) [U.S.] |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 3.5% |
5–10 mL q 4–6 hr |
a, c, d, e, f |
|||||
| Robafen DAC Syrup (Schedule V) [U.S.] |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 1.4% |
10 mL q 4 hr (max 40 mL/day) |
b, c, e, f |
||||
| Robafen DM Syrup (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol 1.4% |
5–10 mL q 4 hr |
b, c |
|||||
| Robitussin A-C Syrup USP (Schedule V) [U.S.] |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 3.5% Sugar free |
10 mL q 4 hr (max 6 doses/day) |
6–12 yrs: 5 mL q 4 hr (max 6 doses/day) |
a, c, d, e, f |
||||
| Syrup (N) [Canada] |
Pheniramine maleate 7.5 mg |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 3.5% |
5–10 mL q 4–6 hr |
6–12 yrs: 2.5–5 mL q 4–6 hr |
b, c, e, f |
|||
| Robitussin with Codeine Syrup (N) [Canada] |
Pheniramine maleate 7.5 mg |
Codeine PO 4 3.3 mg |
Guaifenesin 100 mg |
Alcohol 3.5% |
15 mL q 4–6 hr |
6–12 yrs: 7.5 mL q 4–6 hr |
b, c, e, f |
|||
| Robitussin Cold and Cough Liqui-Gels Capsules USP (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 200 mg |
2 caps q 4 hr (max 8 caps/day) |
6–12 yrs: 1 cap q 4 hr (max 4 caps/day) |
a, d |
||||
| Robitussin Cold, Cough & Flu Liqui-Gels Capsules (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Acetamin- ophen 250 mg |
2 caps q 4 hr (max 8 caps/day) |
6–12 yrs: 1 cap q 4 hr (max 4 caps/day) |
b |
|||
| Robitussin Cough & Cold Oral Solution (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 100 mg |
Alcohol |
10 mL q 6–8 hr (max 4 doses/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6–8 hr (max 4 doses/day) |
b, c |
|||
| Robitussin Cough & Cold Liqui-Fills Capsules USP (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 200 mg |
2 caps q 6 hr (max 4 doses/day) |
6–12 yrs: 1 cap q 6 hr (max 4 doses/day) |
a |
||||
| Robitussin-DAC Syrup (Schedule V) [U.S.] |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol 1.9% Sugar free |
10 mL q 4 hr (max 40 mL/day) |
6–12 yrs: 5 mL q 4 hr |
a, c, e, f |
|||
| Robitussin-DM Oral Solution (OTC) [U.S] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free |
10 mL q 4 hr (max 60 mL/day) |
2–6 yrs: 2.5 mL (max 15 mL/day), 6–12 yrs: 5 mL (max 30 mL/day), q 4 hr |
b, c |
||||
| Syrup (N) [Canada] |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 100 mg |
Alcohol 1.4% |
10 mL q 6–8 hr |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6–8 hr |
b, c |
||||
| Robitussin Night Relief Oral Solution (OTC) [U.S.] |
Pyrilamine maleate 50 mg/30 mL |
Pseudoephedrine HCl 60 mg/ 30 mL |
Dextrometh- orphan HBr 30 mg/ 30 mL |
Acetamin- ophen 650 mg/ 30 mL |
Alcohol free |
30 mL hs or q 6 hr |
b, e |
|||
| Robitussin Night-Time Cold Formula Capsules (OTC) [U.S.] |
Doxylamine succinate 6.25 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
2 caps q 6 hr |
Not recommended |
b |
|||
| Robitussin-PE Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Guaifenesin 100 mg |
Alcohol free |
10 mL q 4 hr (max 40 mL/day) |
2–6 yrs: 2.5 mL (max 10 mL/day), 6–12 yrs: 5 mL (max 20 mL/day), q 4 hr |
b, c |
||||
| Robitussin Pediatric Cough & Cold Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free |
20 mL q 6 hr (max 80 mL/day) |
2–6 yrs: 5 mL (max 20 mL/day), 6–12 yrs: 10 mL (max 40 mL/day), q 6 hr |
b, c |
||||
| Syrup (OTC) [Canada] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free |
20 mL q 6–8 hr |
2–6 yrs: 5 mL, 6–12 yrs: 10 mL, q 6–8 hr |
b, c |
||||
| Robitussin Severe Congestion Liqui-Gels Capsules USP (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Guaifenesin 200 mg |
2 caps q 4 hr (max 8 caps/day) |
6–12 yrs: 1 cap q 4 hr (max 4 caps/day) |
a, d |
|||||
| Rondamine-DM Drops Oral Solution (Rx) [U.S.] |
Carbinoxamine maleate 2 mg/mL |
Pseudoephedrine HCl 25 mg/mL |
Dextrometh- orphan HBr 4 mg/mL |
1–18 mos: 0.25–1 mL q 6 hr |
b, c, e |
|||||
| Rondec-DM Syrup (Rx) [U.S.] |
Carbinoxamine maleate 4 mg |
Pseudoephedrine HCl 60 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol free Sugar free |
5 mL q 6 hr |
18 mos–6 yrs: 2.5 mL, >6 yrs: 5 mL, q 6 hr |
a1 , c, d, e |
|||
| Rondec-DM Drops Oral Solution (Rx) [U.S.] |
Carbinoxamine maleate 2 mg/mL |
Pseudoephedrine HCl 25 mg/mL |
Dextrometh- orphan HBr 4 mg/mL |
Alcohol free Sugar free |
Intended for pediatric use. See Rondec-DM Syrup |
1–3 mos: 0.25 mL, 3–6 mos: 0.50 mL, 6–9 mos: 0.75 mL, 9–18 mos: 1 mL, q 6 hr >18 mos: See Rondec-DM Syrup |
a1 , c, e, h |
|||
| Ru-Tuss DE Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 600 mg |
Scored |
1 tab q 12 hr |
6–12 yrs: 1/2 tab q 12 hr |
b |
||||
| Ru-Tuss Expectorant Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol 10% |
10 mL q 4–6 hr (max 40 mL/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4–6 hr (max 4 doses/day) |
b, c, e, f |
|||
| Ryna-C Liquid Oral Solution (Schedule V) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Alcohol free Dye free Sugar free |
10 mL q 6 hr (max 40 mL/day) |
6–12 yrs: 5 mL q 6 hr |
b, c, e, f |
|||
| Ryna-CX Liquid Oral Solution (Schedule V) [U.S.] |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol free Dye free Sugar free |
10 mL q 6 hr (max 40 mL/day) |
6–12 yrs: 5 mL q 6 hr |
b, c, e, f |
|||
| Rynatuss Tablets (Rx) [U.S.] |
Chlorpheniramine tannate 5 mg |
Ephedrine tannate 10 mg, Phenylephrine tannate 10 mg |
Carbeta- pentane tannate 60 mg |
Scored |
1–2 tabs q 12 hr |
6–12 yrs: 1/2–1 tab q 12 hr |
b, e |
|||
| Rynatuss Pediatric Oral Suspension (Rx) [U.S.] |
Chlorpheniramine tannate 4 mg |
Ephedrine tannate 5 mg, Phenylephrine tannate 5 mg |
Carbeta- pentane tannate 30 mg |
Intended for pediatric use. See Rynatuss Tablets |
2–6 yrs: 2.5–5 mL, 6–12 yrs: 5–10 mL, q 12 hr |
b, c, e, g |
||||
| Safe Tussin 30 Oral Solution (OTC) [U.S.] |
Dextrometh- orphan HBr 30 mg |
Guaifenesin 200 mg |
Alcohol free Sodium free Sugar free Dye free |
10 mL q 6 hr (max 4 doses/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6 hr (max 4 doses/day) |
b, c |
||||
| Scot-Tussin DM Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol free Sugar free |
5 mL q 4 hr or 10 mL q 6–8 hr |
b, c, e |
|||||
| Scot-Tussin Senior Clear Oral Solution (OTC) [U.S.] |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 200 mg |
Phenylalanine Alcohol free Sugar free |
5 mL q 4 hr (max 30 mL/day) |
a |
|||||
| Sildec-DM Syrup (Rx) [U.S.] |
Brompheniramine 4 mg |
Pseudoephedrine HCl 45 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol free |
a, d, e |
|||||
| Silexin Cough Syrup (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free |
20 mL q 6–8 hr |
6–12 yrs: 10 mL q 6–8 hr |
b, c |
||||
| Siltussin DM Syrup (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free |
5–10 mL q 4 hr |
b, c |
|||||
| Sinufed Timecelles Extended-release Capsules (Rx) [U.S.] |
Pseudoephedrine HCl 60 mg |
Guaifenesin 300 mg |
1–2 caps q 12 hr |
6–12 yrs: 1 cap q 12 hr |
b |
|||||
| Sinutab with Codeine Tablets (N) [Canada] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Codeine 8 mg |
Acetamin- ophen 325 mg |
1–2 tabs q 4–6 hr (max 8 tabs/day) |
b, e, f |
||||
| Sinutab Non-Drying No Drowsiness Liquid Caps Capsules USP (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Guaifenesin 200 mg |
2 caps q 4 hr (max 8 caps/day) |
a 2 |
||||||
| Stamoist E Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 500 mg |
Dye free Scored |
1 tab q 12 hr |
b |
|||||
| Statuss Green Oral Solution (Schedule III) [U.S.] |
Chlorpheniramine 2 mg/ 5 mL, Pyrilamine maleate 3.3 mg |
Phenylephrine HCl 5 mg, Pseudoephedrine HCl 3.3 mg/ 5mL |
Hydrocodone bitartrate 2.5 mg |
Alcohol 5% |
b, c, e, f |
|||||
| S-T Forte 2 Oral Solution (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Hydrocodone bitartrate 2.5 mg |
Glycerin 99.7% Alcohol free Sugar free Dye free |
5 mL q 6–8 hr (max 20 mL/day) |
6 mos–1 yr: 10 drops, 1–3 yrs: 20 drops, 3–12 yrs: 2.5 mL, q 6–8 hr |
b, c, e, f |
||||
| Sudafed Children's Cold & Cough Syrup (OTC) [U.S.] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 5 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free |
20 mL q 4 hr (max 4 doses/day) |
2–6 yrs: 5 mL, 6–12 yrs: 10 mL, q 4 hr (max 4 doses/day) |
b, c, d |
|||
| Sudafed Children's Non-Drowsy Cold & Cough Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 5 mg |
Guaifenesin 100 mg |
Alcohol Free Sugar free |
20 mL q 4 hr (max 4 doses/day) |
2–6 yrs: 5 mL, 6–12 yrs: 10 mL, q 4 hr (max 4 doses/day) |
b, c, d |
|||
| Sudafed Cold & Cough Liquid Caps Capsules (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Acetamin- ophen 250 mg |
2 caps q 4 hr (max 8 caps/day) |
Not recommended |
b, c, d |
|||
| Sudafed Cold & Flu Gelcaps Capsules (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Acetamin- ophen 250 mg |
2 caps q 4 hr |
b, d |
||||
| Sudafed Cough & Cold Extra Strength Caplets Tablets (OTC) [Canada] |
Pseudoephedrine HCl 60 mg |
Dextrometh- orphan HBr 30 mg |
Acetamin- ophen 500 mg |
Scored |
1 tab q 4–6 hr (max 4 tabs/day) |
b, d |
||||
| Sudafed DM Oral Solution (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol |
10 mL q 4–6 hr (max 40 mL/day) |
4 mos–2 yr: 1.25 mL 2–5 yrs: 2.5 mL, 6–11 yrs: 5 mL, q 4–6 hr (max 4 doses/day) |
b, c |
||||
| Sudal 60/500 Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 60 mg |
Guaifenesin 500 mg |
Scored |
1–2 tabs q 12 hr |
6–12 yrs: 1/2–1 tab q 12 hr |
a, d |
||||
| Syracol CF Tablets (OTC) [U.S.] |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 200 mg |
2 tabs q 6–8 hr (max 8 tabs/day) |
2–6 yrs: 1/2 tab, 6–12 yrs: 1 tab, q 6–8 hr |
b |
|||||
| Tanta Cough Syrup Syrup (OTC) [Canada] |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 100 mg |
Alcohol 1.4% |
10 mL q 6–8 hr (max 4 doses/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 6–8 hr (max 4 doses/day) |
a |
||||
| TheraFlu Flu, Cold & Cough Medicine for Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 4 mg/packet |
Pseudoephedrine HCl 60 mg/packet |
Dextrometh- orphan HBr 20 mg/packet |
Acetamin- ophen 650 mg packet |
1 packet dissolved in 6-oz cup of hot water q 4 hr (max 4 packets/day) |
b, e |
||||
| TheraFlu Maximum Strength Non-Drowsy Formula Flu, Cold & Cough Medicine for Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 60 mg/packet |
Dextrometh- orphan HBr 30 mg/packet |
Acetamin- ophen 1000 mg/ packet |
1 packet dissolved in 6-oz cup of hot water q 6 hr (max 4 packets/day) |
Not recommended |
b |
||||
| TheraFlu Maximum Strength Non-Drowsy Formula Flu, Cold & Cough Medicine Caplets Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
2 tabs q 6 hr (max 8 tabs/day) |
b |
|||||
| TheraFlu Nighttime Maximum Strength Flu, Cold & Cough for Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 4 mg/ packet |
Pseudoephedrine HCl 60 mg/packet |
Dextrometh- orphan HBr 30 mg/packet |
Acetamin- ophen 1000 mg/ packet |
1 packet dissolved in 6-oz cup of hot water q 6 hr (max 4 packets/day) |
b, e |
||||
| Tolu-Sed DM Syrup (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol 10% Sugar free |
10 mL q 4 hr |
1–6 yrs: 1.25–2.5 mL, 6–12 yrs: 2.5–5 mL, q 4 hr |
b, c |
||||
| Touro DM {59} Extended-release Tablets (Rx) [U.S.] |
Dextrometh- orphan HBr 30 mg |
Guaifenesin 575 mg |
1–2 tabs q 12 hrs (max 4 tabs/day) |
2–6 yrs: 1/2 tab q 12 hrs (max 1 tab/day) 6–12 yrs: 1 tab q 12 hrs (max 2 tabs/day) |
b, d |
|||||
| Touro LA Caplets Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 525 mg |
Scored |
b |
||||||
| Triacin C Cough Syrup (Schedule V) [U.S.] |
Triprolidine HCl 1.25 mg |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
Alcohol 4.3% |
10 mL q 4–6 hr (max 40 mL/day) |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4–6 hr |
b, c, d, e, f |
|||
| Triafed w/Codeine Syrup (Schedule V) [U.S.] |
Triprolidine HCl 1.25 mg |
Pseudoephedrine HCl 30 mg |
Codeine PO 4 10 mg |
10 mL q 4–6 hr (max 40 mL/day) |
b, c, e, f |
|||||
| Triaminic AM Non-Drowsy Cough and Decongestant Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free Dye free |
20 mL q 6 hr (max 80 mL/day) |
2–6 yrs: 5 mL (max 20 mL/day), 6–12 yrs: 10 mL (max 40 mL/day), q 6 hr |
b |
||||
| Triaminic DM DayTime for Children Syrup (OTC) [Canada] |
Dextrometh- orphan HBr 7.5 mg |
Guaifenesin 37.5 mg |
Alcohol 5.5% |
2–6 yrs: 5 mL, 6–12 yrs: 10 mL, q 6–8 hr |
a, e |
|||||
| Triaminic-DM Expectorant Oral Solution (OTC) [Canada] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Guaifenesin 100 mg |
Alcohol 7.1% |
10 mL q 6 hr |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4 hr |
b, c, e |
||
| Triaminic DM NightTime for Children Syrup (OTC) [Canada] |
Chlorpheniramine maleate 1 mg |
Pseudoephedrine HCl 15.0 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free |
20 mL q 6–8 hr |
2–6 yrs: 5 mL, 6–12 yrs: 10 mL, q 6–8 hr |
a, d, e |
|||
| Triaminic Night Time Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 1 mg |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Alcohol free |
20 mL q 6 hr (max 4 doses/day) |
6–12 yrs: 10 mL q 6 hr (max 4 doses/day) |
b, c, e |
|||
| Triaminic Sore Throat Formula Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Acetamin- ophen 160 mg |
Alcohol free |
20 mL q 6 hr (max 4 doses/day) |
2–6 yrs: 5 mL, 6–12 yrs: 10 mL, q 6 hr (max 4 doses/day) |
b, c |
|||
| Triaminicol Syrup (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 12.5 mg |
Dextrometh- orphan HBr 10 mg |
20 mL q 4–6 hr (max 6 doses/day) |
6–12 yrs: 10 mL q 4–6 hr (max 6 doses/day) |
b, c, e |
||||
| Tri-Tannate Plus Pediatric Oral Suspension (Rx) [U.S.] |
Chlorpheniramine tannate 4 mg |
Ephedrine tannate 5 mg, Phenylephrine tannate 5 mg |
Carbeta- pentane tannate 30 mg |
2–<6 yrs: 2.5–10 mL q 12 hr |
b, c, e |
|||||
| Tussafed Syrup (Rx) [U.S.] |
Carbinoxamine maleate 4 mg |
Pseudoephedrine HCl 60 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol free Sugar free |
5 mL q 4–6 hr |
18 mos–6 yrs: 2.5 mL, >6 yrs: 5 mL, q 4–6 hr |
a, c, d, e |
|||
| Tussafed Drops Oral Solution (Rx) [U.S.] |
Carbinoxamine maleate 2 mg/mL |
Pseudoephedrine HCl 25 mg/mL |
Dextrometh- orphan HBr 4 mg/mL |
Alcohol free Sugar free |
1–18 mos: 0.25–1 mL q 6 hr |
b, c, e |
||||
| Tussar DM Syrup (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 5 mg |
Dextrometh- orphan HBr 15 mg |
Alcohol free |
b, c, e |
|||||
| Tussex Cough Syrup (OTC) [U.S.] |
Phenylephrine HCl 5 mg |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
10 mL q 4 hr |
b |
|||||
| Tussigon Tablets (Schedule III) [U.S.] |
Hydrocodone bitartrate 5 mg |
Homatropine MBr ** 1.5 mg Scored |
1 tab q 4–6 hr |
6–12 yrs: 1/2 tab q 4–6 hr |
b, d, e, f |
|||||
| Tussilyn DM Syrup (OTC) [Canada] |
Chlorpheniramine maleate 2.5 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
10 mL q 8 hr |
2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 8 hr |
a |
||||
| Tussionex Oral Suspension (N) [Canada] |
Phenyltoloxamine as resin complex 10 mg |
Hydrocodone as resin complex 5 mg |
Sugar free |
5 mL q 8–12 hr (max 2 doses/day) |
1–5 yrs: 2.5 mL, >5 yrs: 5 mL, q 12 hr (max 2 doses/day) |
b, c, e, f, g |
||||
| Tablets (N) [Canada] |
Phenyltoloxamine as resin complex 10 mg |
Hydrocodone as resin complex 5 mg |
Scored |
1 tab q 8–12 hr (max 2 tabs/day) |
b, e, f |
|||||
| Tussionex Pennkinetic Oral Suspension (Schedule III) [U.S.] |
Chlorpheniramine maleate 8 mg (as polistirex) |
Hydrocodone bitartrate 10 mg (as polistirex) |
Alcohol free |
5 mL q 12 hr |
>6 yrs: 2.5 mL q 12 hr |
b, c, e, f, g |
||||
| Tussi-Organidin DM NR Liquid Oral Solution (Rx) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free |
10 mL q 4 hr (max 6 doses/day) |
6 mos–2 yrs: 0.6–1.25 mL, 2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4 hr (max 6 doses/day) |
a, c, d |
||||
| Tussi-Organidin DM-S NR Liquid Oral Solution (Rx) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free |
10 mL q 4 hr (max 6 doses/day) |
6 mos–2 yrs: 0.6–1.25 mL, 2–6 yrs: 2.5 mL, 6–12 yrs: 5 mL, q 4 hr (max 6 doses/day) |
a, c, d |
||||
| Tussi-Organidin-S NR Liquid Oral Solution (Schedule V) [U.S.] |
Codeine PO 4 10 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free |
10 mL q 4 hr (max 6 doses/day) |
2–6 yrs: 1 mg/kg/day of codeine given in 4 divided doses 6–12 yrs: 5 mL q 4 hr (max 6 doses/day) |
a, c, d, e, f |
||||
| Tussirex Oral Solution (Schedule V) [U.S.] |
Pheniramine maleate 13.3 mg |
Phenylephrine HCl 4.2 mg |
Codeine PO 4 10 mg |
Sodium citrate † 83.3 mg |
Sodium salicylate 83.3 mg |
Caffeine citrate 25 mg Alcohol free With or without sugar |
5 mL q 8 hr |
b, c, e, f |
||
| Tuss-LA Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 500 mg |
Scored |
1 tab q 12 hr |
2–6 yrs: Not recommended 6–12 yrs: 1/2 tab q 12 hr |
b |
||||
| Tusso-DM Oral Solution (Rx) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Iodinated glycerol † 30 mg |
Alcohol free Sugar free |
5–10 mL q 4 hr |
2–6 yrs: 1.25–2.5 mL, 6–12 yrs: 5 mL, q 4 hr |
a, c |
||||
| Tylenol Children's Cold DM Medication Oral Solution (OTC) [Canada] |
Chlorpheniramine maleate 1 mg |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Acetamin- ophen 160 mg |
Alcohol free |
Intended for pediatric use |
2–5 yrs: 5 mL, 6–12 yrs: 10 mL, q 4–6 hr (max 4 doses/day) |
a |
||
| Chewable Tablets (OTC) [Canada] |
Chlorpheniramine maleate 0.5 mg |
Pseudoephedrine HCl 7.5 mg |
Dextrometh- orphan HBr 3.75 mg |
Acetamin- ophen 80 mg |
Phenylalanine |
Intended for pediatric use |
2–5 yrs: 2 tabs, 6–12 yrs: 4 tabs, q 4–6 hr (max 4 doses/day) |
b, i |
||
| Tylenol Cold and Flu for Oral Solution (OTC) [Canada] |
Chlorpheniramine maleate 4 mg/pouch |
Pseudoephedrine HCl 60 mg/ pouch |
Dextrometh- orphan HBr 30 mg/pouch |
Acetamin- ophen 650 mg/ pouch |
Phenylalanine, Sugar 19 grams/pouch |
1 pouch dissolved in 225 mL of hot water q 4–6 hr (max 3 pouches/day) |
Intended for adult use |
b, e |
||
| Tylenol Cold and Flu No Drowsiness Powder for Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 60 mg/ packet |
Dextrometh- orphan HBr 30 mg/packet |
Acetamin- ophen 650 mg/packet |
Phenylalanine 11 mg/packet |
1 packet dissolved in 180 mL of hot water q 6 hr |
b, c |
||||
| Tylenol Cold Medication Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 0.66 mg (2 mg/15 mL) |
Pseudoephedrine HCl 10 mg (30 mg/15 mL) |
Dextrometh- orphan HBr 5 mg (15 mg/15 mL) |
Acetamin- ophen 108.3 mg (325 mg/ 15 mL) |
Alcohol 7% |
15–30 mL q 6 hr |
Intended for adult use |
b, c, e |
||
| Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
2 tabs q 6 hr (max 8 tabs/day) |
6–11 yrs: 1 tab q 6 hr (max 4 tabs/day) |
b, e |
|||
| Tylenol Cold Medication Caplets Tablets (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
2 tabs q 6 hr (max 8 tabs/day) |
6–11 yrs: 1 tab q 6 hr (max 4 tabs/day) |
b, e |
|||
| Tylenol Cold Medication Extra Strength Daytime Caplets Tablets (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
1–2 tabs q 6 hr (max 8 tabs/day) |
Intended for adult use |
b |
||||
| Tylenol Cold Medication Extra Strength Nighttime Caplets Tablets (OTC) [Canada] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
1–2 tabs q 6 hr (max 8 tabs/day) |
Intended for adult use |
b, e |
|||
| Tylenol Cold Medication, Non-Drowsy Caplets Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
2 tabs q 6 hr (max 8 tabs/day) |
6–11 yrs: 1 tab q 6 hr (max 4 tabs/day) |
b, e |
||||
| Tylenol Cold Medication, Non-Drowsy Gelcaps Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
2 tabs q 6 hr (max 8 tabs/day) |
6–11 yrs: 1 tab q 6 hr (max 4 tabs/day) |
b, e |
||||
| Tylenol Cold Medication Regular Strength Daytime Caplets Tablets (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
1–2 tabs q 6 hr (max 8 tabs/day) |
Intended for adult use |
b |
||||
| Tylenol Cold Medication Regular Strength Nighttime Caplets Tablets (OTC) [Canada] |
Chlorpheniramine maleate 2 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 325 mg |
1–2 tabs q 6 hr (max 8 tabs/day) |
Intended for adult use |
b, e |
|||
| Tylenol Cold Multi-Symptom for Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 4 mg/packet |
Pseudoephedrine HCl 60 mg/ packet |
Dextrometh- orphan HBr 30 mg/packet |
Acetamin- ophen 650 mg/ packet |
Phenylalanine 11 mg/packet |
1 packet dissolved in 180 mL of hot water q 6 hr |
Intended for adult use |
b, e |
||
| Tylenol Cough Extra Strength Caplets Tablets (OTC) [Canada] |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
2 tabs q 6–8 hr (max 8 tabs/day) |
b |
||||||
| Tylenol Cough Medication with Decongestant, Regular Strength Oral Suspension (OTC) [Canada] |
Pseudoephedrine HCl 60 mg/15 mL |
Dextrometh- orphan HBr 30 mg/15 mL |
Acetamin- ophen 650 mg/ 15 mL |
15 mL q 6–8 hr (max 60 mL/day) |
a, c |
|||||
| Tylenol Cough Medication Regular Strength Oral Suspension (OTC) [Canada] |
Dextrometh- orphan HBr 30 mg/15 mL |
Acetamin- ophen 650 mg/ 15 mL |
15 mL q 6–8 hr (max 60 mL/day) |
Intended for adult use |
a, c |
|||||
| Tylenol Extra Strength Cold and Flu Medication Powder for Oral Solution (OTC) [Canada] |
Chlorpheniramine maleate 4 mg/pouch |
Pseudoephedrine HCl 60 mg/ pouch |
Dextrometh- orphan HBr 30 mg/pouch |
Acetamin- ophen 1000 mg/ pouch |
Sugar 17.5 grams/ pouch (honey/lemon flavor) Sodium 1.2 grams/ pouch (chicken soup flavor) |
1 pouch dissolved in 225 mL of hot water q 4–6 hr (max 3 pouches/day) |
b, e |
|||
| Tylenol Junior Strength Cold DM Medication Chewable Tablets (OTC) [Canada] |
Chlorpheniramine maleate 1 mg |
Pseudoephedrine HCl 15 mg |
Dextrometh- orphan HBr 7.5 mg |
Acetamin- ophen 160 mg |
Phenylalanine Scored |
2–5 yrs: 1 tab, 6–11 yrs: 2 tabs, q 4–6 hr (max 4 doses/day) |
b, i |
|||
| Tylenol Maximum Strength Flu Gelcaps Tablets (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 15 mg |
Acetamin- ophen 500 mg |
2 tabs q 6 hr (max 8 tabs/day) |
Not recommended |
b |
||||
| Tylenol Multi-Symptom Cough Oral Solution (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 217 mg |
Alcohol 5% |
15 mL q 6–8 hr (max 4 doses/day) |
6–11 yrs: 7.5 mL q 6–8 hr (max 4 doses/day) |
b, c |
||||
| Tylenol Multi-Symptom Cough with Decongestant Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 20 mg |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 217 mg |
Alcohol 5% |
15 mL q 6–8 hr (max 4 doses/day) |
6–11 yrs: 7.5 mL q 6–8 hr (max 4 doses/day) |
b, c |
|||
| Uni-tussin DM Syrup (OTC) [U.S.] |
Dextrometh- orphan HBr 10 mg |
Guaifenesin 100 mg |
Alcohol free |
10 mL q 4 hr |
b, c |
|||||
| Vanex-HD Syrup (Schedule III) [U.S.] |
Chlorpheniramine maleate 2 mg |
Phenylephrine HCl 5 mg |
Hydrocodone bitartrate 1.7 mg |
Alcohol free Dye free |
10 mL q 6–8 hr |
6–12 yrs: 5 mL q 6–8 hr |
b, c, e, f |
|||
| V-Dec-M Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 500 mg |
Scored |
1 tab q 12 hr |
b |
|||||
| Versacaps Extended-release Capsules (Rx) [U.S.] |
Pseudoephedrine HCl 60 mg |
Guaifenesin 300 mg |
1–2 caps q 12 hr |
b |
||||||
| Vicks Children's NyQuil Oral Solution (OTC) [Canada] |
Chlorpheniramine maleate 2 mg/15 mL |
Pseudoephedrine HCl 30 mg/15 mL |
Dextrometh- orphan HBr 15 mg/ 15 mL |
Alcohol free |
Intended for pediatric use |
1–5 yrs: 7.5 mL, 6–11 yrs: 15 mL hs |
b, c, e |
|||
| Vicks Children's NyQuil Cold/Cough Relief Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 2 mg/15 mL |
Pseudoephedrine HCl 30 mg/15 mL |
Dextrometh- orphan HBr 15 mg/15 mL |
Alcohol free |
30 mL q 6 hr (max 4 doses/day) |
6–11 yrs: 15 mL q 6 hr (max 4 doses/day) |
b, c, e |
|||
| Vicks 44 Cough and Cold Relief Non-Drowsy LiquiCaps Capsules (OTC) [U.S.] |
Pseudoephedrine HCl 60 mg |
Dextrometh- orphan HBr 30 mg |
Alcohol free |
1 cap q 6 hr (max 4 caps/day) |
Not recommended |
b |
||||
| Vicks 44D Cough and Head Congestion Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 20 mg (60 mg/15 mL) |
Dextrometh- orphan HBr 10 mg (30 mg/15 mL) |
Alcohol 10% |
15 mL q 6 hr |
b, c |
|||||
| Vicks DayQuil Liquicaps Capsules (OTC) [Canada] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 250 mg |
Alcohol free |
2 caps q 4–6 hr (max 8 caps/day) |
a |
||||
| Vicks DayQuil Multi-Symptom Cold/Flu LiquiCaps Capsules (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 250 mg |
2 caps q 4 hr (max 8 caps/day) |
6–11 yrs: 1 cap q 4 hr (max 4 caps/day) |
b, c |
||||
| Vicks DayQuil Multi-Symptom Cold/Flu Relief Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 30 mg/15 mL |
Dextrometh- orphan HBr 10 mg/ 15 mL |
Acetamin- ophen 325 mg/ 15 mL |
Alcohol free |
30 mL q 4 hr (max 4 doses/day) |
6–11 yrs: 15 mL q 4 hr (max 4 doses/day) |
b, c |
|||
| Vicks 44E Cough & Chest Congestion Oral Solution (OTC) [U.S.] |
Dextrometh- orphan HBr 6.67 mg (20 mg/ 15 mL) |
Guaifenesin 66.7 mg (200 mg/ 15 mL) |
Alcohol 10% |
15 mL q 4 hr (max 90 mL/day) |
b |
|||||
| Vicks Formula 44-D Oral Solution(OTC) [Canada] |
Pseudoephedrine HCl 60 mg/15 mL |
Dextrometh- orphan HBr 30 mg/15 mL |
Alcohol |
15 mL q 6–8 hr (max 60 mL/day) |
b, d, g |
|||||
| Vicks Formula 44-D Pediatric Syrup (OTC) [Canada] |
Pseudoephedrine HCl 10 mg (30 mg/15 mL) |
Dextrometh- orphan HBr 5 mg (15 mg/15 mL) |
Alcohol free |
1–5 yrs: 7.5 mL, 6–11 yrs: 15 mL, q 6–8 hr (max 4 doses/day) |
b, d, g |
|||||
| Vicks Formula 44E Syrup (OTC) [Canada] |
Dextrometh- orphan HBr 20 mg/15 mL |
Guaifenesin 200 mg/ 15 mL |
Alcohol |
15 mL q 4 hr (max 90 mL/day) |
b, d, g |
|||||
| Vicks Formula 44e Pediatric Syrup (OTC) [Canada] |
Dextrometh- orphan HBr 3.3 mg (10 mg/15 mL) |
Guaifenesin 33.3 mg (100 mg/ 15 mL) |
Alcohol free |
1–5 yrs: 7.5 mL, 6–11 yrs: 15 mL, q 4 hr (max 6 doses/day) |
b, d, g |
|||||
| Vicks Formula 44M Syrup (OTC) [Canada] |
Chlorpheniramine maleate 1 mg (4 mg/20 mL) |
Pseudoephedrine HCl 15 mg (60 mg/20 mL) |
Dextrometh- orphan HBr 7.5 mg (30 mg/20 mL) |
Acetamin- ophen 162.5 mg (650 mg/ 20 mL) |
Alcohol |
20 mL q 6–8 hr (max 80 mL/day) |
b, d, e, g |
|||
| Vicks 44M Cough, Cold and Flu Relief Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 1 mg (4 mg/20 mL) |
Pseudoephedrine HCl 15 mg (60 mg/20 mL) |
Dextrometh- orphan HBr 7.5 mg (30 mg/20 mL) |
Acetamin- ophen 162.5 mg (650 mg/ 20 mL) |
Alcohol 10% |
20 mL q 6 hr (max 80 mL/day) |
b, c |
|||
| Vicks NyQuil Oral Solution (OTC) [Canada] |
Doxylamine succinate 12.5 mg/30 mL |
Pseudoephedrine HCl 60 mg/30 mL |
Dextrometh- orphan HBr 30 mg/30 mL |
Acetamin- ophen 1000 mg/ 30 mL |
Alcohol |
30 mL hs or q 6–8 hr (max 90 mL/day) |
b, c, e |
|||
| Vicks NyQuil Hot Therapy for Oral Solution (OTC) [U.S.] |
Doxylamine succinate 12.5 mg/ packet |
Pseudoephedrine HCl 60 mg/ packet |
Dextrometh- orphan HBr 30 mg/ packet |
Acetamin- ophen 1000 mg/ packet |
1 packet dissolved in 6-oz cup of hot water hs or q 6 hr |
Intended for adult use |
b, e |
|||
| Vicks NyQuil LiquiCaps Capsules (OTC) [Canada] |
Doxylamine succinate 6.25 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 250 mg |
Sugar free |
2 caps hs or q 4–6 hr (max 8 caps/day) |
b, e |
|||
| Vicks NyQuil Multi-Symptom Cold/Flu LiquiCaps Capsules (OTC) [U.S.] |
Doxylamine succinate 6.25 mg |
Pseudoephedrine HCl 30 mg |
Dextrometh- orphan HBr 10 mg |
Acetamin- ophen 250 mg |
2 caps q 4 hr (max 8 caps/day) |
Intended for adult use |
b, e |
|||
| Vicks NyQuil Multi-Symptom Cold/Flu Relief Oral Solution (OTC) [U.S.] |
Doxylamine succinate 2 mg (12.5 mg/30 mL) |
Pseudoephedrine HCl 10 mg (60 mg/30 mL) |
Dextrometh- orphan HBr 5 mg (30 mg/ 30 mL) |
Acetamin- ophen 166.6 mg (1000 mg/ 30 mL) |
Alcohol 10% |
30 mL hs or q 6 hr (max 4 doses/day) |
Not recommended |
b, c, e |
||
| Vicks Pediatric 44D Cough & Head Decongestion Oral Solution (OTC) [U.S.] |
Pseudoephedrine HCl 10 mg |
Dextrometh- orphan HBr 5 mg |
Alcohol free |
30 mL q 6 hr (max 4 doses/day) |
2–5 yrs: 7.5 mL, 6–11 yrs: 15 mL, q 6 hr (max 4 doses/day) |
b, c |
||||
| Vicks Children's Cough Syrup (OTC) [U.S.] |
Dextrometh- orphan HBr 3.3 mg |
Guaifenesin 33.3 mg |
Alcohol free |
b, c |
||||||
| Vicks Pediatric 44M Multi-Symptom Cough & Cold Oral Solution (OTC) [U.S.] |
Chlorpheniramine maleate 0.67 mg |
Pseudoephedrine HCl 10 mg |
Dextrometh- orphan HBr 5 mg |
Alcohol free |
30 mL q 6 hr (max 4 doses/day) |
6–11 yrs: 15 mL q 6 hr (max 4 doses/day) |
b, c, e |
|||
| Vicodin Tuss Syrup (Schedule III) [U.S.] |
Hydrocodone bitartrate 5 mg |
Guaifenesin 100 mg |
Alcohol free Sugar free Dye free |
5 mL q 4 hr (max 6 doses/day) |
6–12 yrs: 2.5–5 mL q 4 hr (max 6 doses/day) |
b, c, e, f |
||||
| Zephrex Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 60 mg |
Guaifenesin 400 mg |
1 tab q 6 hr |
Pediatric strength not available |
b |
|||||
| Zephrex-LA Extended-release Tablets (Rx) [U.S.] |
Pseudoephedrine HCl 120 mg |
Guaifenesin 600 mg |
Scored |
1 tab q 12 hr |
Pediatric strength not available |
b |
||||
† Efficacy as expectorant has not been established.
‡ Geriatric patients may be more sensitive to effects of usual adult dose.
§ For appropriate Packaging and storage and Auxiliary labeling information refer to designated letters as follows:
• a—Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a tight container, unless otherwise specified by manufacturer.
• a 1—Store below 30 °C (86 °F), unless otherwise specified by manufacturer. Avoid exposure to excessive heat.
• a 2—Store below 25 °C (77 °F), unless otherwise specified by manufacturer.
• b—Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer.
• c—Protect from freezing.
• d—Protect from light.
• e—Auxiliary labeling: o May cause drowsiness. o Avoid alcoholic beverages.
• f—Auxiliary labeling: o May be habit forming.
• g—Auxiliary labeling: o Shake well.
• h—Dispense in dropper bottle.
• i—Chew well before swallowing.
** Included in subtherapeutic amount to discourage deliberate overdosage.
Strength(s) usually available
U.S.—
See above table.
Revised: 05/27/2002
References
- Product packaging or insert.
- Antihistamines monograph, USP-D1 1991.
- Histalet X package insert (Solvay—US), Rev 5/91, Rec 9/94.
- Triaminic DM Daytime/Nighttime Children's product labels (Sandoz—Canada), Rec 5/94.
- Cotridin Cough Syrup and Expectorant product labels (Technilab—Canada), Rec 7/94.
- NeoCitran product label (Sandoz—Canada), Rec 5/94.
- Calmylin dextromethorphan preparations product monograph (Technilab—Canada), Rev 10/94, Rec 11/94.
- FDA Register; HHS News 2/27/89.
- Calmylin Codeine product label (Technilab—Canada), Rec 7/94.
- Benylin product labels (Warner-Lambert—Canada), Rec 11/94.
- Vicks NyQuil Hot Therapy (Procter & Gamble). In: PDR Physicians' desk reference for nonprescription drugs. 15th ed. 1994. Montvale, NJ: Medical Economics Data Production Co, 1994: 642.
- Safe Tussin 30 product label (Kramer—US), Rec 12/94.
- Drixoral Liquid Caps product label (Schering-Plough—US), Rec 11/94.
- Bromfed-DM package insert (Muro—US), Rec 11/94.
- Bronkaid product label (Sterling—US), Rec 10/93.
- Atuss DM, EX, HD package inserts (Atley—US), Rec 11/94.
- Sudal 60/500, 120/600 package inserts (Atley—US), Rev 5/94, Rec 11/94.
- Benylin Multi-Symptom product label (Parke-Davis—US), Rec 12/94 and 2/95.
- Fenesin DM package insert (Dura—US), Rev 94, Rec 12/94.
- Tussilyn DM product label (Vachon—Canada), Rec 12/94.
- Dimetapp-C product label (Whitehall-Robins—Canada), Rec 12/94.
- Alka-Seltzer Plus Liqui-Gels product labels (Miles—US), Rec 11/94.
- Hycodan package insert (Du Pont). In: PDR Physicians' desk reference. 45th ed. 1991. Oradell, NJ: Medical Economics Data, 1991: 687.
- Actifed DM tablets product label (Wellcome—Canada), Rec 11/94.
- Sudafed Cough & Cold Non-Drowsy product label (Wellcome—Canada), Rec 11/94.
- Sudafed Expectorant Tablets product label (Wellcome—Canada), Rec 11/94.
- Triaminic AM product label (Sandoz—US), Rec 11/94.
- TheraFlu Non-Drowsy Flu, Cold, & Cough tablets product label (Sandoz—US), Rec 11/94.
- Histinex HC package insert (Ethex—US), Rev 6/94, Rec 12/94.
- HycoClear Tuss package insert (Ethex—US), Rev 3/94, Rec 12/94.
- Contac Severe Cold & Flu Non-Drowsy package label (SmithKline Beecham—US), Rec 12/94.
- Contac Severe Cold & Flu Hot Medicine package label (SmithKline Beecham—US), Rec 12/94.
- Ambenyl product label (Parke-Davis—Canada), Rec 12/94.
- Brontex product labels (Procter & Gamble—US), Rec 12/94.
- Contac Day/Night Cold & Flu (SmithKline Beecham). In: PDR Physicians' desk reference for nonprescription drugs. 15th ed. 1994. Montvale, NJ: Medical Economics Data Production Co, 1994: 704.
- Cheracol (Roberts). In: Krogh CME, editor. CPS Compendium of pharmaceuticals and specialties. 29th ed. Ottawa: Canadian Pharmaceutical Association, 1994: 235.
- Olin BR, editor. Drug facts and comparisons. St. Louis: Facts and Comparisons Inc, January 1995: 856.
- Guai-Vent/PSE package insert (Dura—US), Rev 94, Rec 1/95.
- Phenergan product labels (Rhone-Poulenc Rorer—Canada), Rec 1/95.
- Nasabid package insert (Abana—US), Rev 4/94, Rec 1/95.
- Respa-1st package insert (Respa—US), Rev 1/94, Rec 1/95.
- Respa-DM package insert (Respa—US), Rev 1/94, Rec 1/95.
- CoSudafed product information (Burroughs Wellcome—Canada), Rec 1/95.
- Tussi-Organidin liquids package insert (Wallace—US), Rec 8/94, Rec 1/95.
- Novahistex product monographs (Merrell Dow—Canada), Rev 5/90, Rec 1/95.
- Novahistine product monographs (Merrell Dow—Canada), Rev 5/90, Rec 1/95.
- Tylenol product labels (McNeil—Canada), Rec 1/95.
- Saleto-CF product label (Roberts—US), Rev 9/94, Rec 1/95.
- Syracol CF product label (Roberts—US), Rev 9/94, Rec 1/95.
- Sinutab Non-Drying product label (Warner Wellcome—US), Rec 2/95.
- Dimacol (Whitehall—US), per correspondence 9/94.
- Despec-SR package insert (International Ethical—US), Rev 12/93, Rec 3/95.
- SYN-Rx product information (Adams—US), Rec 3/95.
- Tussar product information (Rhone-Poulenc Rorer—US), Rec 7/94.
- Robitussins (Whitehall-Robins). In: Krogh CME, editor. CPS Compendium of pharmaceuticals and specialties. 30th ed. Ottawa: Canadian Pharmaceutical Association, 1995: 1183.
- Statuss Expectorant package insert (Huckaby—US), Rev 7/93, Rec 4/95.
- Humibid Guaifenesin Plus product box (Menly & James—US), Rec 1/98.
- PanMist-JR package insert (Pan American Labs—US), Rev 9/97, Rec 9/98.
- Touro DM package insert (Dartmouth—US), Rev 7/97, Rec 2/98.
- Product Information: Brontex, codeine phosphate/guaifenesin. Proctor and Gamble Pharmaceuticals, Cincinnati, OH, USA (PI revised 10/98), reviewed 6/2000.
- FDA Talk Paper: FDA issues public health warning on phenylpropanolamine. United States Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD 11/2000.
- Red book 2002 Online. Montvale, NJ: Medical Economics Data; 5/13/2002.
